<link rel="stylesheet" href="css/cards.css">
<div style="margin-top: 40px;margin-left:5%;margin-right:5%;">

    <nav aria-label="breadcrumb">
        <ol class="breadcrumb">
            <li class="breadcrumb-item"><a href="index.html">Home</a></li>
            <li class="breadcrumb-item" aria-current="page">Paralytics</li>
            <li class="breadcrumb-item active" aria-current="page">Drugs</li>
        </ol>
    </nav>


    <div class="mainContent">
        <h2>Drugs</h2>
        <br>
        <!-- Nav tabs -->
        <ul class="nav nav-tabs" id="myTab" role="tablist">
            <li class="nav-item">
                <a class="nav-link active" id="pancuronium-tab" data-toggle="tab" href="#pancuronium" role="tab"
                    aria-controls="pancuronium" aria-selected="true">Pancuronium</a>
            </li>
            <li class="nav-item">
                <a class="nav-link" id="CISATRACURIUM-tab" data-toggle="tab" href="#CISATRACURIUM" role="tab"
                    aria-controls="CISATRACURIUM" aria-selected="false">CISATRACURIUM (Nimbex)
                </a>
            </li>
            <li class="nav-item">
                <a class="nav-link" id="Rocuronium-tab" data-toggle="tab" href="#Rocuronium" role="tab"
                    aria-controls="Rocuronium" aria-selected="false">Rocuronium</a>
            </li>
            <li class="nav-item">
                <a class="nav-link" id="Succinylcholine-tab" data-toggle="tab" href="#Succinylcholine" role="tab"
                    aria-controls="Succinylcholine" aria-selected="false">Succinylcholine</a>
            </li>
            <li class="nav-item">
                <a class="nav-link" id="Vecuronium-tab" data-toggle="tab" href="#Vecuronium" role="tab"
                    aria-controls="Vecuronium" aria-selected="false">Vecuronium (Norcuron)
                </a>
            </li>
        </ul>

        <!-- Tab panes -->
        <div class="tab-content">
            <div class="tab-pane active" id="pancuronium" role="tabpanel" aria-labelledby="pancuronium-tab">
                <div class="mainContent">
                    <div id="pancuronium">
                        <div class="card">
                            <a class="collapsed" data-toggle="collapse" href="#pancuroniumCollapseOne" role="button"
                                aria-expanded="false" aria-controls="pancuroniumCollapseOne">
                                <div class="card-header" id="pancuroniumheadingOne">
                                    <h1 class="card-heading">
                                        Dosing
                                    </h1>
                                </div>
                            </a>
                            <div id="pancuroniumCollapseOne" class="collapse" aria-labelledby="pancuroniumheadingOne"
                                data-parent="#pancuronium">
                                <div class="card-body" id="Pancuronium-DOSING">

                                    <ul>
                                        <li>
                                            <a data-toggle="collapse" href="#Pancuronium-DOSINGcollapseOne"
                                                role="button" aria-expanded="false"
                                                aria-controls="Pancuronium-DOSINGcollapseOne">
                                                DOSAGE &amp; INDICATIONS
                                            </a>
                                            <div class="card collapse" id="Pancuronium-DOSINGcollapseOne"
                                                data-parent="#Pancuronium-DOSING">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        <h3> For the treatment of refractory agitation in the
                                                            intensive care unit patient.
                                                            Intravenous dosage</h3>
                                                        <h4>Adults</h4>
                                                        <p> Initial doses of 0.04 to 0.1 mg/kg IV have been recommended
                                                            in
                                                            patients
                                                            with agitation not controlled
                                                            with large doses of neuroleptics, benzodiazepines, or
                                                            morphine.
                                                            Repeated
                                                            doses should be based on
                                                            clinical goals and patient response (e.g., peripheral nerve
                                                            stimulation
                                                            monitoring). NOTE:
                                                            Nondepolarizing muscle relaxants cause paralysis without
                                                            altering
                                                            consciousness; liberal doses of
                                                            morphine or midazolam should be used to ensure tranquility
                                                        </p>
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse" href="#Pancuronium-DOSINGcollapseTwo"
                                                role="button" aria-expanded="false"
                                                aria-controls="Pancuronium-DOSINGcollapseTwo">
                                                MAXIMUM DOSAGE
                                            </a>
                                            <div class="card collapse" id="Pancuronium-DOSINGcollapseTwo"
                                                data-parent="#Pancuronium-DOSING">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        <p class="card-p">
                                                            Specific maximum dosage information is not available. Dosage
                                                            must
                                                            be individualized based on clinical response
                                                        </p>
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse" href="#Pancuronium-DOSINGcollapseThree"
                                                role="button" aria-expanded="false"
                                                aria-controls="Pancuronium-DOSINGcollapseThree">
                                                DOSING CONSIDERATIONS
                                            </a>
                                            <div class="card collapse" id="Pancuronium-DOSINGcollapseThree"
                                                data-parent="#Pancuronium-DOSING">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        <p class="card-p">
                                                            <h3>Hepatic Impairment</h3>
                                                            <p class="card-p">
                                                                Hepatic impairment may prolong the duration of action of
                                                                pancuronium.
                                                                Specific guidelines for
                                                                dosage adjustments in hepatic impairment are not
                                                                available;
                                                                dosage
                                                                reductions may be necessary.
                                                            </p>
                                                            <h3>Renal Impairment</h3>
                                                            <p class="card-p">
                                                                Initial dosage should be modified based on clinical
                                                                goals
                                                                and the degree
                                                                of renal impairment.
                                                                Individualize further dosage based on patient response
                                                                (e.g., peripheral
                                                                nerve stimulation
                                                                monitoring). Renal failure may prolong the duration of
                                                                action of
                                                                pancuronium.
                                                                Dosage adjustments for pediatric patients are as
                                                                follows:
                                                                CrCl > 50 mL/minute/1.73 m2: No initial dosage
                                                                adjustment
                                                                required;
                                                                monitor carefully and adjust
                                                                dosage to clinical effect.
                                                                CrCl 10 to 50 mL/minute/1.73 m2: Administer 50% of
                                                                normal
                                                                dosage;
                                                                monitor carefully and adjust
                                                                dosage to clinical effect.
                                                                CrCl &lt; 10 mL/minute/1.73 m2: Avoid use </p>
                                                        </p>
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                    </ul>

                                </div>
                            </div>
                        </div>
                        <div class="card">
                            <a class="collapsed" data-toggle="collapse" href="#pancuroniumCollapseTwo" role="button"
                                aria-expanded="false" aria-controls="pancuroniumCollapseTwo">
                                <div class="card-header" id="pancuroniumheadingTwo">
                                    <h1 class="card-heading">
                                        CONTRAINDICATIONS / PRECAUTIONS
                                    </h1>
                                </div>
                            </a>
                            <div id="pancuroniumCollapseTwo" class="collapse" aria-labelledby="pancuroniumheadingTwo"
                                data-parent="#pancuronium">
                                <div class="card-body" id="Pancuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                    <ul>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseOne"
                                                role="button" aria-expanded="false"
                                                aria-controls="Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseOne">
                                                General Information
                                            </a>
                                            <div class="card collapse"
                                                id="Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseOne"
                                                data-parent="#Pancuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Pancuronium does not cause sedation or analgesia and should be
                                                        administered
                                                        only after
                                                        unconsciousness has been induced. Amnesia and analgesia should
                                                        be
                                                        adequately
                                                        maintained
                                                        throughout paralyzation. Doses of pancuronium should be
                                                        individualized. Use
                                                        of a peripheral nerve
                                                        stimulator will permit the most advantageous use of pancuronium,
                                                        minimize
                                                        the possibility of
                                                        overdosage or underdosage, and assist in the evaluation of
                                                        recovery.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseTwo"
                                                role="button" aria-expanded="false"
                                                aria-controls="Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseTwo">
                                                Requires an experienced clinician, respiratory insufficiency
                                            </a>
                                            <div class="card collapse"
                                                id="Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseTwo"
                                                data-parent="#Pancuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Neuromuscular blocking agents cause respiratory insufficiency by
                                                        paralyzing
                                                        respiratory muscles.
                                                        Administration requires an experienced clinician who is
                                                        adequately
                                                        trained
                                                        and familiar with the
                                                        actions, characteristics, and hazards of pancuronium. These
                                                        personnel should
                                                        be skilled in airway
                                                        management and respiratory support. Equipment and personnel must
                                                        be
                                                        immediately available for
                                                        intubation and support of ventilation, including administration
                                                        of
                                                        oxygen
                                                        therapy. Adequacy of
                                                        respiration must be assured through assisted or controlled
                                                        ventilation.
                                                        Reversal agents must be
                                                        immediately available.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseThree"
                                                role="button" aria-expanded="false"
                                                aria-controls="Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseThree">
                                                Labor, obstetric delivery, pregnancy
                                            </a>
                                            <div class="card collapse"
                                                id="Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseThree"
                                                data-parent="#Pancuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Use pancuronium during pregnancy only if the benefits outweigh
                                                        the
                                                        risks. It
                                                        is not known whether
                                                        pancuronium can cause fetal harm when administered to a pregnant
                                                        woman or if
                                                        it can affect
                                                        reproduction capacity. Pancuronium may be used in obstetric
                                                        delivery
                                                        (i.e.,
                                                        cesarean section), but
                                                        reversal of pancuronium may be unsatisfactory in patients
                                                        receiving
                                                        magnesium sulfate for toxemia
                                                        of pregnancy because magnesium salts enhance neuromuscular
                                                        blockade.
                                                        Reduce
                                                        pancuronium
                                                        dosage, as indicated, in such cases. It is also recommended that
                                                        the
                                                        interval between pancuronium
                                                        use and labor and obstetric delivery be reasonably short to
                                                        avoid
                                                        clinically
                                                        significant placental
                                                        transfer. Animal reproduction studies of pancuronium have not
                                                        been
                                                        performed.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseFour"
                                                role="button" aria-expanded="false"
                                                aria-controls="Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseFour">
                                                Breast-feeding
                                            </a>
                                            <div class="card collapse"
                                                id="Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseFour"
                                                data-parent="#Pancuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        There are no data on the presence of pancuronium in human milk,
                                                        the
                                                        effects
                                                        on the breast-fed
                                                        infant, or the effects on milk production. The elimination
                                                        half-life
                                                        for
                                                        pancuronium is 1.5 to 3 hours.
                                                        It
                                                        is a bisquaternary ammonium compound and should pass slowly
                                                        through
                                                        biological membranes. If
                                                        trace amounts were excreted into breast milk, quaternary
                                                        ammonium
                                                        muscle
                                                        relaxants are poorly
                                                        absorbed from the gastrointestinal tract. Based on these data,
                                                        breast-feeding could be allowed as
                                                        soon as practically feasible after recovery from a surgical
                                                        procedure.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseFive"
                                                role="button" aria-expanded="false"
                                                aria-controls="Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseFive">
                                                Chronic obstructive pulmonary disease (COPD),pulmonary disease,
                                                respiratory
                                                depression
                                            </a>
                                            <div class="card collapse"
                                                id="Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseFive"
                                                data-parent="#Pancuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Neuromuscular blocking agents can cause respiratory paralysis as
                                                        a
                                                        result of
                                                        respiratory depression
                                                        and should be used with extreme caution in patients with
                                                        pulmonary
                                                        disease
                                                        such as chronic
                                                        obstructive pulmonary disease (COPD). In addition, patients with
                                                        severe
                                                        obesity may be
                                                        predisposed to airway or ventilatory problems which require
                                                        special
                                                        care
                                                        before, during, and after
                                                        treatment with pancuronium.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseSix"
                                                role="button" aria-expanded="false"
                                                aria-controls="Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseSix">
                                                Bromide hypersensitivity, neuromuscular blocking agent hypersensitivity
                                            </a>
                                            <div class="card collapse"
                                                id="Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseSix"
                                                data-parent="#Pancuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Pancuronium is contraindicated in patients known to have
                                                        hypersensitivity to
                                                        pancuronium or a
                                                        bromide hypersensitivity. Pancuronium should be used with
                                                        caution in
                                                        patients with a neuromuscular
                                                        blocking agent hypersensitivity, as cross-reactivity has been
                                                        reported with
                                                        both depolarizing and
                                                        non-depolarizing agents in this class.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseSeven"
                                                role="button" aria-expanded="false"
                                                aria-controls="Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseSeven">
                                                Lung cancer, myasthenia gravis, myopathy, neuromuscular disease, obesity
                                            </a>
                                            <div class="card collapse"
                                                id="Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseSeven"
                                                data-parent="#Pancuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Patients with conditions that impair neuromuscular function can
                                                        experience
                                                        prolonged or
                                                        exaggerated neuromuscular block with nondepolarizing agents.
                                                        These
                                                        conditions include
                                                        myasthenia gravis, myasthenic syndrome associated with small
                                                        cell
                                                        carcinomatosis (Eaton Lambert
                                                        syndrome; originally associated with lung cancer), myopathy, or
                                                        any
                                                        other
                                                        neuromuscular disease.
                                                        Additionally, patients with weak muscle tone and those who
                                                        suffer
                                                        from
                                                        severe obesity are at an
                                                        increased risk for airway and ventilation complications. Use
                                                        vecuronium with
                                                        caution in patients with
                                                        these conditions, and continue to monitor patients carefully
                                                        until
                                                        recovery
                                                        is fully complete.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseEight"
                                                role="button" aria-expanded="false"
                                                aria-controls="Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseEight">
                                                Asthma, cardiac disease, edema
                                            </a>
                                            <div class="card collapse"
                                                id="Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseEight"
                                                data-parent="#Pancuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Neuromuscular blocking agents stimulate histamine release.
                                                        Compared
                                                        with
                                                        other neuromuscular
                                                        blockers, pancuronium produces minimal stimulation, but it
                                                        should be
                                                        used
                                                        with caution in any
                                                        condition in which a significant release of histamine may be
                                                        contraindicated, such as cardiac disease
                                                        or asthma. In addition, use pancuronium with caution in patients
                                                        with
                                                        cardiac disease or other
                                                        conditions that may be associated with a slower circulation
                                                        time.
                                                        Changes in
                                                        the volume of
                                                        distribution related to poor circulation or edema can delay the
                                                        onset of
                                                        neuromuscular blockade.
                                                        Particular care is required when administering subsequent doses
                                                        when
                                                        it is
                                                        uncertain whether
                                                        maximum effect has been attained.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseNine"
                                                role="button" aria-expanded="false"
                                                aria-controls="Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseNine">
                                                Acid/base imbalance, adrenal insufficiency, dehydration, electrolyte
                                                imbalance, hypercalcemia, hypermagnesemia,
                                                hypocalcemia, hypokalemia, hypothermia, metabolic alkalosis, respiratory
                                                acidosis
                                            </a>
                                            <div class="card collapse"
                                                id="Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseNine"
                                                data-parent="#Pancuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Various physiologic states can alter the expected effects of
                                                        pancuronium;
                                                        carefully consider each
                                                        patient's clinical condition when dosing pancuronium and
                                                        monitoring
                                                        the
                                                        patient. Electrolyte
                                                        imbalance can alter a patient's sensitivity to neuromuscular
                                                        blocking agents
                                                        (NMBAs).
                                                        Hypercalcemia can decrease sensitivity to NMBAs, while most
                                                        other
                                                        electrolyte disturbances
                                                        increase sensitivity (e.g., hypokalemia, hypocalcemia,
                                                        hypermagnesemia). Use
                                                        vecuronium
                                                        cautiously in patients with conditions that may lead to
                                                        electrolyte
                                                        imbalances, such as adrenal
                                                        insufficiency. Severe acid/base imbalance may alter a patient's
                                                        sensitivity
                                                        to NMBAs: respiratory
                                                        acidosis may enhance neuromuscular blockade and metabolic
                                                        alkalosis
                                                        may
                                                        counteract it.
                                                        Dehydration and hypothermia can also increase a patient's
                                                        sensitivity to
                                                        NMBAs.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseTen"
                                                role="button" aria-expanded="false"
                                                aria-controls="Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseTen">
                                                Malignant hyperthermia
                                            </a>
                                            <div class="card collapse"
                                                id="Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseTen"
                                                data-parent="#Pancuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Patients with a familial history of malignant hyperthermia
                                                        should be
                                                        treated
                                                        with extreme caution.
                                                        The condition can be precipitated by the use of halogenated
                                                        anesthetics
                                                        because this reaction has
                                                        been attributed to their use, but neuromuscular blocking agents
                                                        (such as
                                                        pancuronium) also may be
                                                        a contributory factor.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseEleven"
                                                role="button" aria-expanded="false"
                                                aria-controls="Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseEleven">
                                                Tachycardia
                                            </a>
                                            <div class="card collapse"
                                                id="Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseEleven"
                                                data-parent="#Pancuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Pancuronium increases the heart rate, probably by a direct
                                                        action on
                                                        the
                                                        acetylcholine receptors in
                                                        the heart. Patients with tachycardia should be treated with
                                                        caution,
                                                        although the effect appears to be
                                                        dose-related and minimal in the usual dosage range.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseTwelve"
                                                role="button" aria-expanded="false"
                                                aria-controls="Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseTwelve">
                                                Renal failure, renal impairment
                                            </a>
                                            <div class="card collapse"
                                                id="Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseTwelve"
                                                data-parent="#Pancuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Pancuronium should be used with caution in patients with renal
                                                        impairment.
                                                        The elimination half-life
                                                        is doubled and plasma clearance is decreased by about 60% in
                                                        patients with
                                                        renal failure.
                                                        Neuromuscular blockade can be prolonged.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseThirteen"
                                                role="button" aria-expanded="false"
                                                aria-controls="Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseThirteen">
                                                Biliary obstruction, hepatic disease
                                            </a>
                                            <div class="card collapse"
                                                id="Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseThirteen"
                                                data-parent="#Pancuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Pancuronium should be used with caution in patients with hepatic
                                                        disease.
                                                        The elimination half-life is
                                                        doubled in patients with biliary obstruction or cirrhosis and
                                                        plasma
                                                        clearance is decreased by &lt;50%
                                                        or about 22%, respectively. In addition, patients with hepatic
                                                        disease may
                                                        have a 50% increase in
                                                        the volume of distribution of pancuronium. This usually results
                                                        in
                                                        the need
                                                        for a higher initial dose to
                                                        achieve adequate muscle relaxation and a prolonged duration of
                                                        action.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseFourteen"
                                                role="button" aria-expanded="false"
                                                aria-controls="Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseFourteen">
                                                Burns
                                            </a>
                                            <div class="card collapse"
                                                id="Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseFourteen"
                                                data-parent="#Pancuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Patients with extensive burns can exhibit a decreased response
                                                        to
                                                        the
                                                        effects of pancuronium.
                                                        Resistance to neuromuscular blockade peaks after about 2 weeks
                                                        and
                                                        gradually
                                                        declines as the
                                                        burns heal. Increased doses of pancuronium may be required in
                                                        these
                                                        patients.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseFiveteen"
                                                role="button" aria-expanded="false"
                                                aria-controls="Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseFiveteen">
                                                Neonates, premature neonates
                                            </a>
                                            <div class="card collapse"
                                                id="Pancuronium-CONTRAINDICATIONS-PRECAUTIONScollapseFiveteen"
                                                data-parent="#Pancuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Pancuronium products contain benzyl alcohol as a preservative.
                                                        For
                                                        this
                                                        reason, FDA-approved
                                                        labeling for some formulations specifically contraindicates use
                                                        in
                                                        neonates
                                                        and premature neonates.
                                                        Large amounts of benzyl alcohol (more than 99 mg/kg/day) have
                                                        been
                                                        associated with gasping
                                                        syndrome in this population. Gasping syndrome is characterized
                                                        by
                                                        central
                                                        nervous depression,
                                                        metabolic acidosis, and gasping respirations. Although normal
                                                        therapeutic
                                                        doses of pancuronium
                                                        would deliver amounts of benzyl alcohol that are substantially
                                                        lower
                                                        than
                                                        those reported to cause
                                                        gasping syndrome, the minimum dose at which toxicity can occur
                                                        is
                                                        not known
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                    </ul>
                                </div>
                            </div>
                        </div>
                        <div class="card">
                            <a class="collapsed" data-toggle="collapse" href="#pancuroniumCollapseThree"
                                aria-expanded="false" aria-controls="pancuroniumCollapseThree">
                                <div class="card-header" id="pancuroniumheadingThree">
                                    <h1 class="card-heading">
                                        BOXED WARNING
                                    </h1>
                                </div>
                            </a>
                            <div id="pancuroniumCollapseThree" class="collapse"
                                aria-labelledby="pancuroniumheadingThree" data-parent="#pancuronium">
                                <div class="card-body">
                                    <h5>Requires an experienced clinician, respiratory insufficiency</h5>
                                    Neuromuscular blocking agents cause respiratory insufficiency by paralyzing
                                    respiratory muscles.
                                    Administration requires an experienced clinician who is adequately trained and
                                    familiar with the
                                    actions, characteristics, and hazards of pancuronium. These personnel should be
                                    skilled in airway
                                    management and respiratory support. Equipment and personnel must be immediately
                                    available for
                                    intubation and support of ventilation, including administration of oxygen
                                    therapy. Adequacy of
                                    respiration must be assured through assisted or controlled ventilation. Reversal
                                    agents must be
                                    immediately available.
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="tab-pane" id="CISATRACURIUM" role="tabpanel" aria-labelledby="CISATRACURIUM-tab">
                <div class="mainContent">
                    <div id="CISATRACURIUM">
                        <div class="card">
                            <a class="collapsed" data-toggle="collapse" href="#CISATRACURIUMCollapseOne" role="button"
                                aria-expanded="false" aria-controls="CISATRACURIUMCollapseOne">
                                <div class="card-header" id="CISATRACURIUMheadingOne">
                                    <h1 class="card-heading">
                                        Dosing
                                    </h1>
                                </div>
                            </a>
                            <div id="CISATRACURIUMCollapseOne" class="collapse"
                                aria-labelledby="CISATRACURIUMheadingOne" data-parent="#CISATRACURIUM">
                                <div class="card-body" id="CISATRACURIUM-Dosing">
                                    <ul>
                                        <li>
                                            <a data-toggle="collapse" href="#CISATRACURIUM-DosingcollapseOne"
                                                role="button" aria-expanded="false"
                                                aria-controls="CISATRACURIUM-DosingcollapseOne">
                                                DOSAGE &amp; INDICATIONS
                                            </a>
                                            <div class="card collapse" id="CISATRACURIUM-DosingcollapseOne"
                                                data-parent="#CISATRACURIUM-Dosing">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        <h3>To provide adequate neuromuscular blockade in mechanically
                                                            ventilated patients in the intensive care unit.
                                                            Intravenous dosage</h3>
                                                        <h3>Healthy Adults</h3>
                                                        <p>An infusion rate of 3 mcg/kg/minute (range: 0.5 to 10.2
                                                            mcg/kg/minute)
                                                            intravenously should provide
                                                            adequate neuromuscular blockade. There may be wide
                                                            interpatient
                                                            variability in dosage
                                                            requirements and these may increase or decrease with time.
                                                            After
                                                            recovery from neuromuscular
                                                            block, readministration of a bolus dose may be necessary to
                                                            quickly
                                                            reestablish NMB prior to
                                                            reinstitution of the infusion.
                                                        </p>
                                                        <h3>Adults with myasthenia gravis</h3>
                                                        <p>In patients with neuromuscular disease such as myasthenia
                                                            gravis,
                                                            use of
                                                            peripheral nerve
                                                            stimulator monitoring and an initial dose of 0.02 mg/kg or
                                                            less
                                                            intravenously is recommended to
                                                            assess the level of neuromuscular blockade and to monitor
                                                            dosage
                                                            requirements.
                                                        </p>
                                                    </div>
                                                </div>
                                            </div>
                                        </li>

                                        <li>
                                            <a data-toggle="collapse" href="#CISATRACURIUM-DosingcollapseTwo"
                                                role="button" aria-expanded="false"
                                                aria-controls="CISATRACURIUM-DosingcollapseTwo">
                                                MAXIMUM DOSAGE
                                            </a>
                                            <div class="card collapse" id="CISATRACURIUM-DosingcollapseTwo"
                                                data-parent="#CISATRACURIUM-Dosing">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        <b>Adults:</b>0.4 mg/kg IV; individualize maintenance doses.
                                                        <br>
                                                        <b>Elderly:</b>0.4 mg/kg IV; individualize maintenance
                                                        doses.<br>
                                                        <b>Adolescents:</b>0.4 mg/kg IV; individualize maintenance
                                                        doses.<br>
                                                        <b>Children:</b>>= 2 years: 0.15 mg/kg IV for; individualize
                                                        maintenance
                                                        doses.<br>
                                                        <b>&lt; 2 years:</b> 0.15 mg/kg IV.<br>
                                                        <b>Infants:</b> 0.15 mg/kg IV
                                                    </div>
                                                </div>
                                            </div>
                                        </li>

                                        <li>
                                            <a data-toggle="collapse" href="#CISATRACURIUM-DosingcollapseThree"
                                                role="button" aria-expanded="false"
                                                aria-controls="CISATRACURIUM-DosingcollapseThree">
                                                DOSING CONSIDERATIONS
                                            </a>
                                            <div class="card collapse" id="CISATRACURIUM-DosingcollapseThree"
                                                data-parent="#CISATRACURIUM-Dosing">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        <h3>Hepatic Impairment</h3>
                                                        Specific guidelines for dosage adjustments in hepatic impairment
                                                        are
                                                        not
                                                        available; it appears that
                                                        no dosage adjustments are needed.
                                                        <h3>Renal Impairment</h3>
                                                        Specific guidelines for dosage adjustments in renal impairment
                                                        are
                                                        not
                                                        available; it appears that no
                                                        dosage adjustments are needed. Extending the interval between
                                                        cisatracurium
                                                        administration and
                                                        the intubation attempt may be required to achieve adequate
                                                        intubation
                                                        conditions; slower times to
                                                        the onset of complete neuromuscular block were observed in
                                                        patients
                                                        with
                                                        renal dysfunction.
                                                        <br>
                                                        Intermittent hemodialysis
                                                        The effects of hemofiltration, hemodialysis, and hemoperfusion
                                                        on
                                                        plasma
                                                        levels of cisatracurium
                                                        and its metabolites are unknown
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                    </ul>
                                </div>
                            </div>
                        </div>
                        <div class="card">
                            <a class="collapsed" data-toggle="collapse" href="#CISATRACURIUMCollapseTwo" role="button"
                                aria-expanded="false" aria-controls="CISATRACURIUMCollapseTwo">
                                <div class="card-header" id="CISATRACURIUMheadingTwo">
                                    <h1 class="card-heading">
                                        CONTRAINDICATIONS / PRECAUTIONS
                                    </h1>
                                </div>
                            </a>
                            <div id="CISATRACURIUMCollapseTwo" class="collapse"
                                aria-labelledby="CISATRACURIUMheadingTwo" data-parent="#CISATRACURIUM">
                                <div class="card-body" id="CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONS">
                                    <ul>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseOne"
                                                role="button" aria-expanded="false"
                                                aria-controls="CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseOne">
                                                General Information
                                            </a>
                                            <div class="card collapse"
                                                id="CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseOne"
                                                data-parent="#CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Cisatracurium does not cause sedation or analgesia and should be
                                                        administered only after
                                                        unconsciousness has been induced. Amnesia and analgesia should
                                                        be
                                                        adequately
                                                        maintained
                                                        throughout paralyzation. Doses of cisatracurium should be
                                                        individualized.
                                                        Use of a peripheral nerve
                                                        stimulator will permit the most advantageous use of
                                                        cisatracurium,
                                                        minimize
                                                        the possibility of
                                                        overdosage or underdosage, and assist in the evaluation of
                                                        recovery.
                                                        Because of its intermediate onset of action, cisatracurium is
                                                        not
                                                        recommended for rapid sequence
                                                        endotracheal intubation.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseTwo"
                                                role="button" aria-expanded="false"
                                                aria-controls="CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseTwo">
                                                Geriatric, myasthenia gravis, myopathy,
                                                neuromuscular disease, obesity
                                            </a>
                                            <div class="card collapse"
                                                id="CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseTwo"
                                                data-parent="#CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Patients with conditions that impair neuromuscular function can
                                                        experience
                                                        prolonged or
                                                        exaggerated neuromuscular blockade after receiving
                                                        nondepolarizing
                                                        agents.
                                                        These conditions
                                                        include myasthenia gravis, myasthenic syndrome (Eaton Lambert
                                                        syndrome),
                                                        myopathy, or any
                                                        other neuromuscular disease. A lower maximum initial bolus of
                                                        0.02
                                                        mg/kg is
                                                        recommended in these
                                                        patients. Extubation is recommended only after the patient has
                                                        recovered
                                                        significantly from
                                                        neuromuscular blockade. Consider use of a reversal agent in
                                                        cases
                                                        where
                                                        residual paralysis is more
                                                        likely to occur. Because the time to neuromuscular blockade is
                                                        approximately
                                                        1 minute slower in
                                                        geriatric patients compared to younger patients, consider
                                                        extending
                                                        the
                                                        interval between
                                                        administering cisatracurium and attempting intubation by at
                                                        least 1
                                                        minute
                                                        to achieve adequate
                                                        intubation conditions. Use a peripheral nerve stimulator to
                                                        determine the
                                                        adequacy of muscle
                                                        relaxation for the purposes of intubation and the timing and
                                                        amounts
                                                        of
                                                        subsequent doses. Patients
                                                        with hemiparesis or paraparesis may demonstrate resistance to
                                                        cisatracurium
                                                        in the affected limbs.
                                                        To avoid inaccurate dosing, perform neuromuscular monitoring on
                                                        a
                                                        non-paretic limb. Additionally,
                                                        patients with weak muscle tone and those who suffer from severe
                                                        obesity are
                                                        at an increased risk for
                                                        airway and ventilation complications. Use cisatracurium with
                                                        caution
                                                        in
                                                        patients with these
                                                        conditions, and continue to monitor patients carefully until
                                                        recovery is
                                                        fully complete.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseThree"
                                                role="button" aria-expanded="false"
                                                aria-controls="CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseThree">
                                                Asthma, chronic obstructive pulmonary disease
                                                (COPD), pulmonary disease,
                                                respiratory depression
                                            </a>
                                            <div class="card collapse"
                                                id="CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseThree"
                                                data-parent="#CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Use neuromuscular blocking agents (NMBAs) with caution in
                                                        patients
                                                        with
                                                        asthma or other
                                                        pulmonary conditions. NMBAs stimulate histamine release, which
                                                        could
                                                        exacerbate asthma. In
                                                        addition, NMBAs cause respiratory muscle paralysis; residual
                                                        muscle
                                                        weakness
                                                        and decreased
                                                        respiratory function (respiratory depression) can persist even
                                                        after
                                                        drug
                                                        discontinuation. Use NMBAs
                                                        with caution in patients with pulmonary disease and conditions
                                                        associated
                                                        with low pulmonary
                                                        function reserve, such as chronic obstructive pulmonary disease
                                                        (COPD).
                                                        Carefully monitor
                                                        respiratory status and adequacy of ventilation after drug
                                                        recovery
                                                        until the
                                                        patient is clearly
                                                        stabilized.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseFour"
                                                role="button" aria-expanded="false"
                                                aria-controls="CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseFour">
                                                Burns
                                            </a>
                                            <div class="card collapse"
                                                id="CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseFour"
                                                data-parent="#CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Patients with burns have been shown to develop resistance to
                                                        nondepolarizing
                                                        neuromuscular
                                                        blocking agents. The extent of altered response depends upon the
                                                        size of the
                                                        burn and the time
                                                        elapsed since the burn injury. Cisatracurium has not been
                                                        studied in
                                                        burn
                                                        patients; however, due to
                                                        its structural similarity to atracurium, the possibility of
                                                        increased dosage
                                                        requirements and a
                                                        shortened duration of action must be considered if cisatracurium
                                                        is
                                                        administered to burn patients.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseFive"
                                                role="button" aria-expanded="false"
                                                aria-controls="CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseFive">
                                                Acid/base imbalance, adrenal insufficiency,
                                                dehydration, electrolyte imbalance,
                                                hypercalcemia, hypermagnesemia, hypocalcemia, hypokalemia, hypothermia,
                                                metabolic acidosis, metabolic alkalosis, respiratory acidosis,
                                                respiratory
                                                alkalosis
                                            </a>
                                            <div class="card collapse"
                                                id="CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseFive"
                                                data-parent="#CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Various physiologic states can alter the expected effects of
                                                        cisatracurium;
                                                        carefully consider each
                                                        patient's clinical condition when dosing cisatracurium and
                                                        monitoring the
                                                        patient. Cachectic and
                                                        debilitated patients are more sensitive to neuromuscular
                                                        blocking
                                                        agents
                                                        (NMBAs). Electrolyte
                                                        imbalance can alter a patient's sensitivity to NMBAs.
                                                        Hypercalcemia
                                                        can
                                                        decrease sensitivity to
                                                        NMBAs, while most other electrolyte disturbances increase
                                                        sensitivity (e.g.,
                                                        hypokalemia,
                                                        hypocalcemia, hypermagnesemia). Use cisatracurium cautiously in
                                                        patients
                                                        with conditions that may
                                                        lead to electrolyte imbalances, such as adrenal insufficiency.
                                                        Severe
                                                        acid/base imbalance may alter
                                                        a patient's sensitivity to NMBAs: metabolic alkalosis, metabolic
                                                        acidosis,
                                                        and respiratory acidosis
                                                        may enhance neuromuscular blockade and/or prolong recovery time,
                                                        while
                                                        respiratory alkalosis
                                                        reduces the potency of the drug. Dehydration and hypothermia can
                                                        also
                                                        increase a patient's
                                                        sensitivity to NMBAs.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseSix"
                                                role="button" aria-expanded="false"
                                                aria-controls="CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseSix">
                                                Malignant hyperthermia
                                            </a>
                                            <div class="card collapse"
                                                id="CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseSix"
                                                data-parent="#CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Because malignant hyperthermia can develop in the absence of
                                                        established
                                                        triggering agents, be
                                                        prepared to recognize and treat malignant hyperthermia in any
                                                        patient
                                                        undergoing general
                                                        anesthesia. Cisatracurium has not been studied in malignant
                                                        hyperthermia-susceptible patients.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseSeven"
                                                role="button" aria-expanded="false"
                                                aria-controls="CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseSeven">
                                                Neonates, premature neonates
                                            </a>
                                            <div class="card collapse"
                                                id="CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseSeven"
                                                data-parent="#CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        The multidose vials (10 mL) of cisatracurium contain benzyl
                                                        alcohol
                                                        as a
                                                        preservative and are
                                                        contraindicated for use in neonates and premature neonates
                                                        because
                                                        these
                                                        patients are more likely
                                                        to develop benzyl alcohol toxicity. When using the multiple dose
                                                        vials in
                                                        infants consider the
                                                        combined daily metabolic load of benzyl alcohol from all
                                                        sources.
                                                        Benzyl
                                                        alcohol dosages of 99
                                                        mg/kg/day or more have been associated with gasping syndrome in
                                                        this
                                                        population. Gasping
                                                        syndrome is characterized by central nervous system depression,
                                                        metabolic
                                                        acidosis, and gasping
                                                        respirations. The minimum amount of benzyl alcohol at which
                                                        serious
                                                        adverse
                                                        reactions may occur
                                                        is not known. Single-use vials of cisatracurium do not contain
                                                        benzyl
                                                        alcohol. The safety and efficacy
                                                        of cisatracurium have not been established in neonates.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseEight"
                                                role="button" aria-expanded="false"
                                                aria-controls="CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseEight">
                                                Neuromuscular blocking agent hypersensitivity
                                            </a>
                                            <div class="card collapse"
                                                id="CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseEight"
                                                data-parent="#CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Cisatracurium is contraindicated in patients with known
                                                        cisatracurium
                                                        hypersensitivity. Although rare,
                                                        severe anaphylactic or anaphylactoid reactions to neuromuscular
                                                        blockers
                                                        have been reported;
                                                        some cases have been fatal. Cisatracurium should be used with
                                                        caution in
                                                        patients with a
                                                        neuromuscular blocking agent hypersensitivity, as
                                                        cross-reactivity
                                                        has been
                                                        reported with both
                                                        depolarizing and non-depolarizing agents in this class.
                                                        Immediate
                                                        availability of appropriate
                                                        emergency treatment for anaphylaxis is advised.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseNine"
                                                role="button" aria-expanded="false"
                                                aria-controls="CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseNine">
                                                Accidental exposure, requires a specialized care
                                                setting, requires an
                                                experienced
                                                clinician, respiratory insufficiency
                                            </a>
                                            <div class="card collapse"
                                                id="CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseNine"
                                                data-parent="#CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Administration of cisatracurium requires an experienced
                                                        clinician
                                                        familiar
                                                        with the actions,
                                                        characteristics, and hazards of neuromuscular blockade.
                                                        Neuromuscular
                                                        blocking agents (NMBAs)
                                                        cause respiratory insufficiency by paralyzing respiratory
                                                        muscles;
                                                        administration requires a
                                                        specialized care setting. Uses cisatracurium only when necessary
                                                        equipment
                                                        and personnel skilled
                                                        in airway management are immediately available. Adequacy of
                                                        respiration must
                                                        be assured through
                                                        assisted or controlled ventilation. Reversal agents should also
                                                        be
                                                        available. Accidental exposure to a
                                                        NMBA in a patient for whom it is not intended can be fatal.
                                                        Confirm
                                                        proper
                                                        medication selection and
                                                        store NMBAs with the cap and ferrule intact, in a manner that
                                                        minimizes the
                                                        possibility of selecting
                                                        the wrong product. Ensure that the intended dose is clearly
                                                        labeled
                                                        and
                                                        communicated.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseTen"
                                                role="button" aria-expanded="false"
                                                aria-controls="CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseTen">
                                                Hepatic disease, renal disease, renal failure,
                                                renal impairment
                                            </a>
                                            <div class="card collapse"
                                                id="CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseTen"
                                                data-parent="#CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Patients with renal impairment or hepatic disease receiving
                                                        extended
                                                        administration of cisatracurium
                                                        may be at higher risk of seizures. Monitor the level of
                                                        neuromuscular
                                                        blockade during long-term
                                                        cisatracurium administration with a nerve stimulator to titrate
                                                        cisatracurium administration to the
                                                        patients' needs and limit exposure to toxic metabolites.
                                                        Cisatracurium-treated patients with renal
                                                        disease, including renal failure, or hepatic impairment may have
                                                        higher
                                                        metabolite concentrations,
                                                        including laudanosine, than patients with normal renal and
                                                        hepatic
                                                        function.
                                                        Laudanosine, an active
                                                        metabolite of cisatracurium, has been associated with seizures
                                                        in
                                                        animals.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseEleven"
                                                role="button" aria-expanded="false"
                                                aria-controls="CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseEleven">
                                                Pregnancy
                                            </a>
                                            <div class="card collapse"
                                                id="CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseEleven"
                                                data-parent="#CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        There are no adequate and well controlled studies of
                                                        cisatracurium
                                                        in human
                                                        pregnancy. Animal
                                                        studies in pregnant rats administered cisatracurium during
                                                        organogenesis at
                                                        doses equivalent to 0.4-
                                                        to 12-times the AUC exposure in humans after a bolus dose of 0.2
                                                        mg/kg IV
                                                        revealed no maternal or
                                                        fetal toxicity or teratogenic effects. The effects of
                                                        neuromuscular
                                                        blocking
                                                        agents may be enhanced
                                                        by magnesium salts administered for the management of
                                                        preeclampsia
                                                        or
                                                        eclampsia of pregnancy.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseTwelve"
                                                role="button" aria-expanded="false"
                                                aria-controls="CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseTwelve">
                                                Breast-feeding
                                            </a>
                                            <div class="card collapse"
                                                id="CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONScollapseTwelve"
                                                data-parent="#CISATRACURIUM-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        It is not known whether cisatracurium is present in human milk.
                                                        Consider the
                                                        developmental and
                                                        health benefits of breast-feeding along with the mother's
                                                        clinical
                                                        need for
                                                        cisatracurium and any
                                                        potential adverse effects on the breast-fed infant from
                                                        cisatracurium or the
                                                        underlying maternal
                                                        condition. Cisatracurium undergoes rapid and spontaneous
                                                        (Hofmann
                                                        elimination) degradation in the
                                                        plasma with an elimination half-life of 22 minutes; metabolites
                                                        are
                                                        not
                                                        biologically active.
                                                        Neuromuscular blockers have poor oral bioavailability. Based on
                                                        these data,
                                                        lactation could be
                                                        allowed as soon as practically feasible after short-term use
                                                        during
                                                        a
                                                        surgical procedure. The effects
                                                        from long-term use are unknown.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                    </ul>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="tab-pane" id="Rocuronium" role="tabpanel" aria-labelledby="Rocuronium-tab">
                <div class="mainContent">
                    <div id="Rocuronium">
                        <div class="card">
                            <a class="collapsed" data-toggle="collapse" href="#RocuroniumCollapseOne" role="button"
                                aria-expanded="false" aria-controls="RocuroniumCollapseOne">
                                <div class="card-header" id="RocuroniumheadingOne">
                                    <h1 class="card-heading">
                                        Dosing
                                    </h1>
                                </div>
                            </a>
                            <div id="RocuroniumCollapseOne" class="collapse" aria-labelledby="RocuroniumheadingOne"
                                data-parent="#Rocuronium">
                                <div class="card-body" id="Rocuronium-Dosing">
                                    <ul>
                                        <li>
                                            <a data-toggle="collapse" href="#Rocuronium-DosingcollapseOne" role="button"
                                                aria-expanded="false" aria-controls="Rocuronium-DosingcollapseOne">
                                                DOSAGE &amp; INDICATIONS
                                            </a>
                                            <div class="card collapse" id="Rocuronium-DosingcollapseOne"
                                                data-parent="#Rocuronium-Dosing">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        <h3>For the maintenance of neuromuscular blockade and
                                                            paralysis (e.g., during
                                                            surgery or mechanical ventilation).
                                                            Intermittent Intravenous dosage</h3>
                                                        <h4>Adults</h4>
                                                        After the initial intubating dose (0.6 mg/kg IV), maintenance
                                                        doses
                                                        must be
                                                        individualized and
                                                        administered only after there is evidence of spontaneous
                                                        recovery of
                                                        neuromuscular function.
                                                        According to the manufacturer, doses of 0.1, 0.15, or 0.2 mg/kg
                                                        IV,
                                                        given
                                                        after neuromuscular
                                                        blockade returns to 25% of control, provides a median of 12
                                                        (range:
                                                        2 to 31
                                                        minutes), 17 (range: 6 to
                                                        50 minutes), or 24 (range: 7 to 69 minutes) minutes of clinical
                                                        block under
                                                        balanced anesthesia,
                                                        respectively.

                                                        <h4>Infants, Children, and Adolescents</h4>
                                                        0.075 to 0.15 mg/kg/dose IV as needed after initial paralysis is
                                                        achieved.
                                                        Adjust the dose and interval as needed to maintain adequate
                                                        paralysis.
                                                        <h4>Neonates</h4>
                                                        0.075 to 0.15 mg/kg/dose IV as needed after initial paralysis is
                                                        achieved.
                                                        Adjust the dose and interval as needed to maintain adequate
                                                        paralysis.
                                                        <h4>Continuous Intravenous Infusion dosage</h4>
                                                        Adults
                                                        Initial infusion rate is 10 to 12 mcg/kg/minute (0.6 to 0.72
                                                        mg/kg/hour) IV
                                                        only after there is evidence
                                                        of spontaneous recovery from the intubating dose. Additional
                                                        bolus
                                                        doses may
                                                        be needed if
                                                        neuromuscular blockade returns to more than 10% of control. Once
                                                        desired
                                                        level of neuromuscular
                                                        blockade is reached, infusion rates must be individualized. In
                                                        clinical
                                                        trials, infusion rates ranged
                                                        from 4 to 16 mcg/kg/minute (0.24 to 0.96 mg/kg/hour).
                                                        <h4>Infants, Children, and Adolescents</h4>
                                                        5 to 12 mcg/kg/minute (0.3 to 0.72 mg/kg/hour) IV after initial
                                                        paralysis is
                                                        achieved.
                                                        Children (2 to 11 years) generally have the largest dosage
                                                        requirement.
                                                        <h4>Neonates</h4>
                                                        5 to 12 mcg/kg/minute (0.3 to 0.72 mg/kg/hour) IV after initial
                                                        paralysis is
                                                        achieved.
                                                        Neonates generally have the lowest dosage requirement and should
                                                        be
                                                        initiated at the lower end of
                                                        the dosing range.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse" href="#Rocuronium-DosingcollapseTwo" role="button"
                                                aria-expanded="false" aria-controls="Rocuronium-DosingcollapseTwo">
                                                MAXIMUM DOSAGE
                                            </a>
                                            <div class="card collapse" id="Rocuronium-DosingcollapseTwo"
                                                data-parent="#Rocuronium-Dosing">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        <h4>Adults &amp; Geriatric</h4>
                                                        1.2 mg/kg IV for intubation; individualize maintenance doses
                                                        based
                                                        on
                                                        clinical response.
                                                        <h4>Adolescents, Children, Infants &amp; Neonates.</h4>
                                                        1.2 mg/kg/dose IV for RSI; individualize maintenance doses based
                                                        on
                                                        clinical
                                                        response.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse" href="#Rocuronium-DosingcollapseThree"
                                                role="button" aria-expanded="false"
                                                aria-controls="Rocuronium-DosingcollapseThree">
                                                DOSING CONSIDERATIONS
                                            </a>
                                            <div class="card collapse" id="Rocuronium-DosingcollapseThree"
                                                data-parent="#Rocuronium-Dosing">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        <h4>Hepatic Impairment</h4>
                                                        Specific guidelines for dosage adjustments in hepatic impairment
                                                        are
                                                        not
                                                        available.
                                                        Patients with hepatic impairment may have a prolonged clinical
                                                        effect up to
                                                        1.5 times that of patients
                                                        with normal hepatic function. In addition, patients with hepatic
                                                        dysfunction
                                                        have a larger volume of
                                                        distribution and may require larger doses to initially achieve
                                                        adequate
                                                        neuromuscular blockade.
                                                        <h4>Renal Impairment</h4>
                                                        Specific guidelines for dosage adjustments in renal impairment
                                                        are
                                                        not
                                                        available.
                                                        Patients with renal failure may have greater variability in
                                                        duration
                                                        of
                                                        clinical effect; follow usual
                                                        dosing guidelines and individualize the dose to the needs of the
                                                        patient.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                    </ul>
                                </div>
                            </div>
                        </div>
                        <div class="card">
                            <a class="collapsed" data-toggle="collapse" href="#RocuroniumCollapseTwo" role="button"
                                aria-expanded="false" aria-controls="RocuroniumCollapseTwo">
                                <div class="card-header" id="RocuroniumheadingTwo">
                                    <h1 class="card-heading">
                                        CONTRAINDICATIONS / PRECAUTIONS
                                    </h1>
                                </div>
                            </a>
                            <div id="RocuroniumCollapseTwo" class="collapse" aria-labelledby="RocuroniumheadingTwo"
                                data-parent="#Rocuronium">
                                <div class="card-body" id="Rocuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                    <ul>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseOne"
                                                role="button" aria-expanded="false"
                                                aria-controls="Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseOne">
                                                General Information
                                            </a>
                                            <div class="card collapse"
                                                id="Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseOne"
                                                data-parent="#Rocuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Rocuronium does not cause sedation or analgesia and should be
                                                        administered
                                                        only after
                                                        unconsciousness has been induced. Amnesia and analgesia should
                                                        be
                                                        adequately
                                                        maintained
                                                        throughout paralyzation. Doses of rocuronium should be
                                                        individualized. Use
                                                        of a peripheral nerve
                                                        stimulator will permit the most advantageous use of rocuronium,
                                                        minimize the
                                                        possibility of
                                                        overdosage or underdosage, and assist in the evaluation of
                                                        recovery.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseTwo"
                                                role="button" aria-expanded="false"
                                                aria-controls="Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseTwo">
                                                Accidental exposure, requires a specialized care
                                                setting, requires an
                                                experienced
                                                clinician, respiratory insufficiency
                                            </a>
                                            <div class="card collapse"
                                                id="Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseTwo"
                                                data-parent="#Rocuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Administration of rocuronium requires an experienced clinician
                                                        familiar with
                                                        the actions,
                                                        characteristics, and hazards of neuromuscular blockade.
                                                        Neuromuscular
                                                        blocking agents cause
                                                        respiratory insufficiency by paralyzing respiratory muscles;
                                                        administration
                                                        requires a specialized care
                                                        setting. Rocuronium should be used only when necessary equipment
                                                        and
                                                        personnel skilled in airway
                                                        management are immediately available. Adequacy of respiration
                                                        must
                                                        be
                                                        assured through assisted
                                                        or controlled ventilation. Reversal agents should also be
                                                        available.
                                                        Accidental exposure to a
                                                        neuromuscular blocking agent (NMBA) in a patient for whom it is
                                                        not
                                                        intended
                                                        can be fatal. Confirm
                                                        proper medication selection and store NMBAs with the cap and
                                                        ferrule
                                                        intact,
                                                        in a manner that
                                                        minimizes the possibility of selecting the wrong product. Ensure
                                                        that the
                                                        intended dose is clearly
                                                        labeled and communicated.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseThree"
                                                role="button" aria-expanded="false"
                                                aria-controls="Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseThree">
                                                Ascites, hepatic disease
                                            </a>
                                            <div class="card collapse"
                                                id="Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseThree"
                                                data-parent="#Rocuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Rocuronium should be administered cautiously in patients with
                                                        hepatic
                                                        disease. Patients with
                                                        hepatic impairment have a significantly increased elimination
                                                        half-life,
                                                        which results in a longer
                                                        duration of action. In addition, patients with significant
                                                        hepatic
                                                        impairment and/or ascites have a
                                                        marked increase in their volume of distribution, making it more
                                                        difficult to
                                                        achieve adequate
                                                        neuromuscular blockade with standard doses.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseFour"
                                                role="button" aria-expanded="false"
                                                aria-controls="Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseFour">
                                                Asthma, chronic lung disease (CLD), chronic
                                                obstructive pulmonary disease
                                                (COPD), pulmonary disease, respiratory depression
                                            </a>
                                            <div class="card collapse"
                                                id="Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseFour"
                                                data-parent="#Rocuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">

                                                        Use neuromuscular blocking agents (NMBAs) with caution in
                                                        patients
                                                        with
                                                        asthma or other
                                                        pulmonary conditions. NMBAs stimulate histamine release, which
                                                        could
                                                        exacerbate asthma.
                                                        Compared with other NMBAs, rocuronium produces little or no
                                                        histamine
                                                        release. While some
                                                        experts consider rocuronium to be an NMBA of choice in asthmatic
                                                        patients,
                                                        it should be used with
                                                        caution in those with any condition in which a release of
                                                        histamine
                                                        may be
                                                        contraindicated. In
                                                        addition, NMBAs cause respiratory muscle paralysis; residual
                                                        muscle
                                                        weakness
                                                        and decreased
                                                        respiratory function (respiratory depression) can persist even
                                                        after
                                                        drug
                                                        discontinuation. Use NMBAs
                                                        with caution in patients with pulmonary disease and conditions
                                                        associated
                                                        with low pulmonary
                                                        function reserve, such as neonatal chronic lung disease (CLD) or
                                                        chronic
                                                        obstructive pulmonary
                                                        disease (COPD). Carefully monitor respiratory status and
                                                        adequacy of
                                                        ventilation after drug recovery
                                                        until the patient is clearly stabilized.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseFive"
                                                role="button" aria-expanded="false"
                                                aria-controls="Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseFive">
                                                Acid/base imbalance, adrenal insufficiency, dehydration, electrolyte
                                                imbalance,
                                                hypercalcemia, hypermagnesemia, hypocalcemia, hypokalemia, hypothermia,
                                                metabolic acidosis, metabolic alkalosis, respiratory acidosis,
                                                respiratory
                                                alkalosis
                                            </a>
                                            <div class="card collapse"
                                                id="Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseFive"
                                                data-parent="#Rocuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Various physiologic states can alter the expected effects of
                                                        rocuronium;
                                                        carefully consider each
                                                        patient's clinical condition when dosing rocuronium and
                                                        monitoring
                                                        the
                                                        patient. Cachectic and
                                                        debilitated patients are more sensitive to neuromuscular
                                                        blocking
                                                        agents
                                                        (NMBAs). Electrolyte
                                                        imbalance can alter a patient's sensitivity to NMBAs.
                                                        Hypercalcemia
                                                        can
                                                        decrease sensitivity to
                                                        NMBAs, while most other electrolyte disturbances increase
                                                        sensitivity (e.g.,
                                                        hypokalemia,
                                                        hypocalcemia, hypermagnesemia). Use rocuronium cautiously in
                                                        patients with
                                                        conditions that may
                                                        lead to electrolyte imbalances, such as adrenal insufficiency.
                                                        Severe
                                                        acid/base imbalance may alter
                                                        a patient's sensitivity to NMBAs: metabolic alkalosis, metabolic
                                                        acidosis,
                                                        and respiratory acidosis
                                                        may enhance neuromuscular blockade and/or prolong recovery time,
                                                        while
                                                        respiratory alkalosis
                                                        reduces the potency of the drug. Dehydration and hypothermia can
                                                        also
                                                        increase a patient's
                                                        sensitivity to NMBAs.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseSix"
                                                role="button" aria-expanded="false"
                                                aria-controls="Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseSix">
                                                Geriatric, myasthenia gravis, myopathy,
                                                neuromuscular disease, obesity
                                            </a>
                                            <div class="card collapse"
                                                id="Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseSix"
                                                data-parent="#Rocuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Patients with conditions that impair neuromuscular function can
                                                        experience
                                                        prolonged or
                                                        exaggerated neuromuscular blockade after receiving
                                                        nondepolarizing
                                                        agents.
                                                        These conditions
                                                        include myasthenia gravis, myasthenic syndrome (Eaton Lambert
                                                        syndrome),
                                                        myopathy, or any
                                                        other neuromuscular disease. Geriatric patients may be at
                                                        increased
                                                        risk for
                                                        residual neuromuscular
                                                        block. The use of a peripheral nerve stimulator to assess the
                                                        level
                                                        of
                                                        neuromuscular block and to
                                                        monitor dosage requirements is recommended. Extubation is
                                                        recommended only
                                                        after the patient
                                                        has recovered significantly from neuromuscular blockade.
                                                        Consider
                                                        use of a
                                                        reversal agent in cases
                                                        where residual paralysis is more likely to occur. Additionally,
                                                        patients
                                                        with weak muscle tone and
                                                        those who suffer from severe obesity are at an increased risk
                                                        for
                                                        airway and
                                                        ventilation
                                                        complications. Use rocuronium with caution in patients with
                                                        these
                                                        conditions, and continue to
                                                        monitor patients carefully until recovery is fully complete.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseSeven"
                                                role="button" aria-expanded="false"
                                                aria-controls="Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseSeven">
                                                Malignant hyperthermia
                                            </a>
                                            <div class="card collapse"
                                                id="Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseSeven"
                                                data-parent="#Rocuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Malignant hyperthermia can be precipitated by many drugs used in
                                                        anesthetic
                                                        practice, including
                                                        halogenated anesthetics and depolarizing neuromuscular blocking
                                                        agents
                                                        (e.g., succinylcholine). It
                                                        is unknown whether rocuronium is capable of triggering
                                                        hyperthermia.
                                                        Patients with a personal or
                                                        familial history of malignant hyperthermia should be treated
                                                        with
                                                        extreme
                                                        caution.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseEight"
                                                role="button" aria-expanded="false"
                                                aria-controls="Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseEight">
                                                Infants, neonates
                                            </a>
                                            <div class="card collapse"
                                                id="Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseEight"
                                                data-parent="#Rocuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Neonates and infants are more sensitive to the effects of
                                                        rocuronium
                                                        compared to older patients;
                                                        they may take longer to recover from neuromuscular blockade.
                                                        Monitor
                                                        patients carefully during and
                                                        after administration. Rocuronium is not recommended by the
                                                        manufacturer for
                                                        rapid sequence
                                                        intubation in pediatric patients due to a lack of data; however,
                                                        it
                                                        is used
                                                        off-label in pediatric
                                                        patients
                                                        for this indication.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseNine"
                                                role="button" aria-expanded="false"
                                                aria-controls="Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseNine">
                                                Labor, obstetric delivery, pregnancy
                                            </a>
                                            <div class="card collapse"
                                                id="Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseNine"
                                                data-parent="#Rocuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        There are no adequate and well-controlled studies of rocuronium
                                                        in
                                                        pregnant
                                                        women. Use
                                                        rocuronium during pregnancy only if the potential benefit
                                                        justifies
                                                        the
                                                        potential risk to the fetus.
                                                        Animal data reveal no teratogenic effects of rocuronium.
                                                        Rocuronium
                                                        has been
                                                        studied in labor and
                                                        obstetric delivery (caesarean section) in a limited number of
                                                        patients.
                                                        Rocuronium is not
                                                        recommended for rapid sequence induction in caesarean section
                                                        patients. When
                                                        used with
                                                        thiopental for rapid sequence induction of anesthesia for
                                                        caesarean
                                                        section,
                                                        no neonate had APGAR
                                                        scores greater than 7 at 5 minutes. Umbilical venous plasma
                                                        concentrations
                                                        were 18% of maternal
                                                        concentrations at delivery. It is not known whether muscle
                                                        relaxants
                                                        administered during labor and
                                                        vaginal delivery have immediate or delayed adverse effects on
                                                        the
                                                        baby or
                                                        increase the likelihood
                                                        that resuscitation of the newborn will be necessary.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseTen"
                                                role="button" aria-expanded="false"
                                                aria-controls="Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseTen">
                                                Breast-feeding
                                            </a>
                                            <div class="card collapse"
                                                id="Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseTen"
                                                data-parent="#Rocuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        There are limited data regarding the use of rocuronium during
                                                        breast-feeding. Due to poor oral
                                                        absorption and its short duration of action, it is not likely
                                                        that
                                                        rocuronium would reach the infant's
                                                        bloodstream. No adverse effects, including dizziness and
                                                        drowsiness,
                                                        occurred in 4 infants of
                                                        breast-feeding mothers who underwent various urgent surgeries
                                                        during
                                                        which
                                                        rocuronium was used
                                                        to facilitate intubation. Breast-feeding resumed 90 minutes to 5
                                                        hours after
                                                        anesthesia.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseEleven"
                                                role="button" aria-expanded="false"
                                                aria-controls="Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseEleven">
                                                Cardiac disease, edema
                                            </a>
                                            <div class="card collapse"
                                                id="Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseEleven"
                                                data-parent="#Rocuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Use rocuronium with caution in patients with cardiac disease or
                                                        other
                                                        conditions that may be
                                                        associated with a slower circulation time. Changes in the volume
                                                        of
                                                        distribution related to poor
                                                        circulation or edema can delay the onset of neuromuscular
                                                        blockade.
                                                        Particular care is required in
                                                        administering subsequent doses when it is uncertain whether
                                                        maximum
                                                        effect
                                                        has been attained.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseTwelve"
                                                role="button" aria-expanded="false"
                                                aria-controls="Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseTwelve">
                                                Pulmonary hypertension, valvular heart disease
                                            </a>
                                            <div class="card collapse"
                                                id="Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseTwelve"
                                                data-parent="#Rocuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Use rocuronium with caution in patients with pulmonary
                                                        hypertension
                                                        or
                                                        valvular heart disease
                                                        because it has been associated with transient increases
                                                        pulmonary
                                                        vascular
                                                        resistance.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseThriteen"
                                                role="button" aria-expanded="false"
                                                aria-controls="Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseThriteen">
                                                Bromide hypersensitivity, neuromuscular blocking
                                                agent hypersensitivity
                                            </a>
                                            <div class="card collapse"
                                                id="Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseThriteen"
                                                data-parent="#Rocuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Rocuronium is contraindicated in patients known to have a
                                                        rocuronium
                                                        bromide
                                                        hypersensitivity.
                                                        Rocuronium is also contraindicated for use by patients with a
                                                        neuromuscular
                                                        blocking agent
                                                        hypersensitivity, as cross-reactivity has been reported with
                                                        both
                                                        depolarizing and non-depolarizing
                                                        agents in this class. Immediate availability of appropriate
                                                        emergency
                                                        treatment for anaphylaxis is
                                                        advised.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseFourteen"
                                                role="button" aria-expanded="false"
                                                aria-controls="Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseFourteen">
                                                Burns
                                            </a>
                                            <div class="card collapse"
                                                id="Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseFourteen"
                                                data-parent="#Rocuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Rocuronium's ability to produce neuromuscular blockade decreases
                                                        significantly in patients with
                                                        burns. Resistance to blockade usually develops in patients with
                                                        burns of
                                                        more than 10% total body
                                                        surface area, approximately 1 week after thermal injury.
                                                        Increased
                                                        doses may
                                                        be required in burn
                                                        patients; alteration in drug effect may be seen for up to 1
                                                        year.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseFiveteen"
                                                role="button" aria-expanded="false"
                                                aria-controls="Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseFiveteen">
                                                Alcoholism, bradycardia, cardiac arrhythmias,
                                                coronary artery disease, diabetes
                                                mellitus, females, heart failure, hypertension, hypomagnesemia,
                                                malnutrition,
                                                myocardial infarction, QT prolongation, thyroid disease
                                            </a>
                                            <div class="card collapse"
                                                id="Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseFiveteen"
                                                data-parent="#Rocuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Analysis of electrocardiogram (ECG) data in pediatric patients
                                                        suggests
                                                        concomitant use of
                                                        rocuronium and general anesthetics (halothane, sevoflurane,
                                                        isoflurane, and
                                                        nitrous oxide) can
                                                        cause QT prolongation. Use rocuronium in combination with
                                                        general
                                                        anesthetics with caution in
                                                        patients with cardiac disease or other conditions that may
                                                        increase
                                                        the risk
                                                        of QT prolongation
                                                        including cardiac arrhythmias, congenital long QT syndrome,
                                                        heart
                                                        failure,
                                                        bradycardia, myocardial
                                                        infarction, hypertension, coronary artery disease,
                                                        hypomagnesemia,
                                                        hypokalemia, hypocalcemia, or
                                                        in patients receiving medications known to prolong the QT
                                                        interval
                                                        or cause
                                                        electrolyte imbalances.
                                                        Females, patients with diabetes mellitus, thyroid disease,
                                                        malnutrition,
                                                        alcoholism, or hepatic
                                                        impairment may also be at increased risk for QT prolongation.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseSixteen"
                                                role="button" aria-expanded="false"
                                                aria-controls="Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseSixteen">
                                                Renal failure
                                            </a>
                                            <div class="card collapse"
                                                id="Rocuronium-CONTRAINDICATIONS-PRECAUTIONScollapseSixteen"
                                                data-parent="#Rocuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Rocuronium should be used with caution and careful monitoring in
                                                        patients
                                                        with renal failure as
                                                        clinical duration within this population is more variable than
                                                        in
                                                        patients
                                                        with normal renal function.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                    </ul>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="tab-pane" id="Succinylcholine" role="tabpanel" aria-labelledby="Succinylcholine-tab">
                <div class="mainContent">
                    <div id="Succinylcholine">
                        <div class="card">
                            <a class="collapsed" data-toggle="collapse" href="#SuccinylcholineCollapseOne" role="button"
                                aria-expanded="false" aria-controls="SuccinylcholineCollapseOne">
                                <div class="card-header" id="SuccinylcholineheadingOne">
                                    <h1 class="card-heading">
                                        Dosing
                                    </h1>
                                </div>
                            </a>
                            <div id="SuccinylcholineCollapseOne" class="collapse"
                                aria-labelledby="SuccinylcholineheadingOne" data-parent="#Succinylcholine">
                                <div class="card-body" id="Succinylcholine-Dosing">
                                    <ul>
                                        <li>
                                            <a data-toggle="collapse" href="#Succinylcholine-DosingcollapseOne"
                                                role="button" aria-expanded="false"
                                                aria-controls="Succinylcholine-DosingcollapseOne">
                                                DOSAGE &amp; INDICATIONS
                                            </a>
                                            <div class="card collapse" id="Succinylcholine-DosingcollapseOne"
                                                data-parent="#Succinylcholine-Dosing">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        <h3>For neuromuscular blockade.
                                                            NOTE: In pediatric patients, the use of succinylcholine
                                                            should
                                                            be
                                                            limited to
                                                            emergent intubations or when immediate securing of the
                                                            airway is
                                                            needed.
                                                            In
                                                            general, nondepolarizing neuromuscular blocking agents are
                                                            preferred for
                                                            routine
                                                            elective surgery or prolonged paralysis.
                                                            For neuromuscular blockade during short surgical procedures.
                                                        </h3>
                                                        <h4>Intravenous dosage</h4>
                                                        <h4>Adults</h4>
                                                        Average dose is 0.6 mg/kg IV (range 0.3 to 1.1 mg/kg) given over
                                                        10
                                                        to 30
                                                        seconds. Additional
                                                        doses, if necessary, are administered in accordance with the
                                                        patient's
                                                        response. A test dose of 0.1
                                                        mg/kg IV may be given initially to assess individual patient
                                                        response and
                                                        recovery time.
                                                        <h4>Intramuscular dosage</h4>
                                                        <h4>Adults</h4>
                                                        A dose of up to 3 to 4 mg/kg IM may be given, but the total dose
                                                        must not
                                                        exceed 150 mg.
                                                        <h4>For neuromuscular blockade during long surgical procedures.
                                                        </h4>
                                                        <h4>Continuous Intravenous Infusion dosage</h4>
                                                        <h4>Adults</h4>
                                                        Solutions containing 0.1% to 0.2% succinylcholine in 5% Dextrose
                                                        Injection
                                                        or 0.9% Sodium
                                                        Chloride Injection (or other appropriate diluent) are usually
                                                        infused IV at
                                                        rate of 2.5 mg/minute for up
                                                        to one hour, but the rate requirements may range from 0.5 to 10
                                                        mg/minute
                                                        depending on the
                                                        individual patient characteristics and response.
                                                        <h4>Intermittent Intravenous Injection dosage</h4>
                                                        <h4>Adults</h4>
                                                        Initial dose is 0.3 to 1.1 mg/kg intermittent IV injection,
                                                        followed
                                                        by
                                                        additional doses of 0.04 to 0.07
                                                        mg/kg as needed to maintain adequate relaxation.
                                                        <h3>For control of muscle contractions during electroconvulsive
                                                            therapy (ECT).</h3>
                                                        <h4>Intravenous dosage</h4>
                                                        <h4>Adults</h4>
                                                        1030 mg IV given about 1 minute before ECT. Dosage for the
                                                        individual
                                                        patient must be
                                                        determined based on his/her size and physical condition.
                                                        <h4>Intramuscular dosage</h4>
                                                        <h4>Adults</h4>
                                                        A dose of up to 34 mg/kg IM may be given, but the total dose
                                                        must
                                                        not
                                                        exceed 150 mg.
                                                        <h4>For muscular relaxation during rapid-sequence intubation.
                                                        </h4>
                                                        NOTE: In pediatric patients, the use of succinylcholine should
                                                        be
                                                        limited to
                                                        emergent intubations or when immediate securing of the airway is
                                                        needed. In
                                                        general, the use of a nondepolarizing neuromuscular blocking
                                                        agent
                                                        is
                                                        preferred
                                                        to avoid the rare risk of succinylcholine-induced acute
                                                        rhabdomyolysis with
                                                        hyperkalemia and asystole.
                                                        <h4>Intravenous dosage</h4>
                                                        <h4>Adults</h4>
                                                        1.5 mg/kg IV. Onset of intubating conditions usually occurs
                                                        within
                                                        30 to 60
                                                        seconds and persists 5 to
                                                        15 minutes after a single dose.
                                                        Infants, Children, and Adolescents 6 months to 17 years
                                                        1 to 2 mg/kg IV. In general, younger patients require larger
                                                        doses;
                                                        some
                                                        experts recommend 2
                                                        mg/kg IV for infants and toddlers, 1.5 mg/kg IV for older
                                                        children,
                                                        and 1
                                                        mg/kg IV for adolescents.
                                                        Onset of intubating conditions usually occurs within 30 to 60
                                                        seconds and
                                                        persists 3 to 12 minutes
                                                        after a single dose.
                                                        <h4>Neonates and Infants younger than 6 months</h4>
                                                        2 mg/kg/dose IV; range 1 to 3 mg/kg/dose IV. May repeat 1
                                                        mg/kg/dose
                                                        IV if
                                                        intubating conditions
                                                        are not attained within an adequate time period (1 to 5
                                                        minutes).
                                                        Max: 4
                                                        mg/kg per intubation
                                                        attempt. Onset of intubating conditions usually occurs within 30
                                                        to
                                                        60
                                                        seconds and persists 3 to 12
                                                        minutes after a single dose.
                                                        <h4>Intramuscular dosage</h4>
                                                        <h4>Adults</h4>
                                                        4 mg/kg IM (Max: 150 mg); use only if IV route not accessible.
                                                        Onset
                                                        of
                                                        intubating conditions usually
                                                        occurs within 5 to 6 minutes, but may be seen within 2 to 3
                                                        minutes.
                                                        Infants, Children, and Adolescents
                                                        3 to 4 mg/kg IM; doses up to 5 mg/kg IM may be necessary in
                                                        infants
                                                        younger
                                                        than 6 months. Max:
                                                        150 mg/dose. This route should only be used if the IV route is
                                                        not
                                                        accessible. Onset of intubating
                                                        conditions usually occurs within 2 to 5 minutes and persists 10
                                                        to
                                                        30
                                                        minutes after a single dose.
                                                        <h4>Neonates</h4>
                                                        2 to 4 mg/kg IM; this route should only be used if the IV route
                                                        is
                                                        not
                                                        accessible. Onset of intubating
                                                        conditions usually occurs within 2 to 5 minutes and persists 10
                                                        to
                                                        30
                                                        minutes after a single dose.
                                                        Indicates off-label use
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse" href="#Succinylcholine-DosingcollapseTwo"
                                                role="button" aria-expanded="false"
                                                aria-controls="Succinylcholine-DosingcollapseTwo">
                                                MAXIMUM DOSAGE
                                            </a>
                                            <div class="card collapse" id="Succinylcholine-DosingcollapseTwo"
                                                data-parent="#Succinylcholine-Dosing">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        <h4>Adults</h4>
                                                        Maximum dose is always dependent upon patient response.
                                                        Short procedures: 1.1 mg/kg IV over 10 to 30 seconds; 150 mg IM.
                                                        Long procedures: 10 mg/minute continuous IV infusion (0.1% to
                                                        0.2%
                                                        succinylcholine IV solution) or
                                                        1.1 mg/kg intermittent IV infusion followed by additional doses
                                                        of
                                                        0.04 to
                                                        0.07 mg/kg as needed to
                                                        maintain adequate relaxation.
                                                        <h4>Geriatric</h4>
                                                        Maximum dose is always dependent upon patient response.
                                                        For short procedures: 1.1 mg/kg IV over 10 to 30 seconds.
                                                        For long procedures: 10 mg/minute continuous IV infusion (0.1%
                                                        to
                                                        0.2%
                                                        succinylcholine IV solution)
                                                        or 1.1 mg/kg intermittent IV infusion followed by additional
                                                        doses
                                                        of 0.04
                                                        to 0.07 mg/kg as needed to
                                                        maintain adequate relaxation.
                                                        <h4>Adolescents &amp; Children</h4>
                                                        2 mg/kg/dose IV; 4 mg/kg/dose IM (Max: 150 mg/dose IM).
                                                        <h4>Infants</h4>
                                                        6 to 11 months: 2 mg/kg/dose IV; 4 mg/kg/dose IM.
                                                        1 to 5 months: 3 mg/kg/dose IV (Max: 4 mg/kg IV per intubation
                                                        attempt); 5
                                                        mg/kg/dose IM.
                                                        <h4>Neonates</h4>
                                                        3 mg/kg/dose IV (Max: 4 mg/kg IV per intubation attempt); 4
                                                        mg/kg/dose IM.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse" href="#Succinylcholine-DosingcollapseThree"
                                                role="button" aria-expanded="false"
                                                aria-controls="Succinylcholine-DosingcollapseThree">
                                                DOSING CONSIDERATIONS
                                            </a>
                                            <div class="card collapse" id="Succinylcholine-DosingcollapseThree"
                                                data-parent="#Succinylcholine-Dosing">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        <h4>Hepatic Impairment</h4>
                                                        Specific guidelines for dosage adjustments in hepatic impairment
                                                        are
                                                        not
                                                        available; it appears that
                                                        no dosage adjustments are needed.
                                                        <h4>Renal Impairment</h4>
                                                        Specific guidelines for dosage adjustments in renal impairment
                                                        are
                                                        not
                                                        available; it appears that no
                                                        dosage adjustments are needed.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                    </ul>
                                </div>
                            </div>
                        </div>
                        <div class="card">
                            <a class="collapsed" data-toggle="collapse" href="#SuccinylcholineCollapseTwo" role="button"
                                aria-expanded="false" aria-controls="SuccinylcholineCollapseTwo">
                                <div class="card-header" id="SuccinylcholineheadingTwo">
                                    <h1 class="card-heading">
                                        CONTRAINDICATIONS / PRECAUTIONS
                                    </h1>
                                </div>
                            </a>
                            <div id="SuccinylcholineCollapseTwo" class="collapse"
                                aria-labelledby="SuccinylcholineheadingTwo" data-parent="#Succinylcholine">
                                <div class="card-body" id="Succinylcholine-CONTRAINDICATIONS-PRECAUTIONS">
                                    <ul>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseOne"
                                                role="button" aria-expanded="false"
                                                aria-controls="Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseOne">
                                                General Information
                                            </a>
                                            <div class="card collapse"
                                                id="Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseOne"
                                                data-parent="#Succinylcholine-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Succinylcholine does not cause sedation or analgesia and ideally
                                                        should be
                                                        administered only after
                                                        unconsciousness has been induced; however, in emergent
                                                        life-threatening
                                                        situations, it may be
                                                        necessary to administer succinylcholine prior to
                                                        unconsciousness.
                                                        Every
                                                        effort should be made to
                                                        avoid patient distress; amnesia and analgesia should be
                                                        adequately
                                                        maintained throughout
                                                        paralyzation. Doses of succinylcholine should be individualized.
                                                        With
                                                        prolonged administration of
                                                        succinylcholine, the characteristic depolarization block (Phase
                                                        I
                                                        block) can
                                                        change to a
                                                        nondepolarizing block (Phase II block). Prolonged respiratory
                                                        muscle
                                                        paralysis or weakness may be
                                                        observed in patients experiencing this transition to Phase II
                                                        block.
                                                        Anticholinesterase agents (e.g.,
                                                        neostigmine) will potentiate succinylcholine-induced Phase I
                                                        block
                                                        and, if
                                                        Phase II block is
                                                        suspected, diagnosis with a peripheral nerve stimulator should
                                                        precede the
                                                        administration of a
                                                        reversal agent. In general, use of a peripheral nerve stimulator
                                                        will permit
                                                        the most advantageous
                                                        use of a neuromuscular blocking agent, minimize the possibility
                                                        of
                                                        overdosage or underdosage, and
                                                        assist in the evaluation of recovery.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseTwo"
                                                role="button" aria-expanded="false"
                                                aria-controls="Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseTwo">
                                                Burns, digitalis toxicity, Guillain-Barre syndrome,
                                                hyperkalemia, trauma
                                            </a>
                                            <div class="card collapse"
                                                id="Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseTwo"
                                                data-parent="#Succinylcholine-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Succinylcholine is contraindicated in patients after the acute
                                                        phase
                                                        of
                                                        injury after major burns,
                                                        multiple trauma, extensive denervation of skeletal muscle, or
                                                        upper
                                                        motor
                                                        neuron injury.
                                                        Succinylcholine administration to such patients can cause severe
                                                        hyperkalemia, which can result in
                                                        cardiac arrest. Risk for hyperkalemia in such patients increases
                                                        over time
                                                        and usually peaks 7 to 10
                                                        days after the injury; however, the precise onset and duration
                                                        of
                                                        the risk
                                                        period are unknown. Risk is
                                                        dependent on extent and location of injury. Additionally,
                                                        succinylcholine
                                                        should be administered with
                                                        great caution in patients with electrolyte imbalances and those
                                                        who
                                                        take
                                                        digoxin and may have
                                                        digitalis toxicity, as succinylcholine-induced hyperkalemia may
                                                        cause
                                                        serious cardiac arrhythmias
                                                        and cardiac arrest. Succinylcholine should not be used in any
                                                        patient with a
                                                        serum potassium more
                                                        than 5.5 mEq/L. Chronic abdominal infections, subarachnoid
                                                        hemorrhage,
                                                        tetanus, disuse atrophy,
                                                        Guillain-Barre syndrome, and degenerative nervous system
                                                        disorders
                                                        may also
                                                        increase the risk for
                                                        hyperkalemia.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseThree"
                                                role="button" aria-expanded="false"
                                                aria-controls="Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseThree">
                                                Bradycardia, children, infants, malignant
                                                hyperthermia, myopathy, neonates,
                                                rhabdomyolysis
                                            </a>
                                            <div class="card collapse"
                                                id="Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseThree"
                                                data-parent="#Succinylcholine-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Succinylcholine is contraindicated in patients with a personal
                                                        or
                                                        familial
                                                        history of malignant
                                                        hyperthermia and/or skeletal muscle myopathy. Malignant
                                                        hyperthermia
                                                        may be
                                                        precipitated by
                                                        succinylcholine; concomitant use of volatile anesthetics may
                                                        further
                                                        increase the risk of developing
                                                        this hypermetabolic state. Use succinylcholine with caution in
                                                        neonates,
                                                        infants, children, and
                                                        adolescents; in general, the use of succinylcholine should be
                                                        limited to
                                                        very urgent clinical
                                                        situations.
                                                        There have been rare reports of ventricular dysrhythmias and
                                                        fatal
                                                        cardiac
                                                        arrest secondary to
                                                        rhabdomyolysis with hyperkalemia, primarily in healthy appearing
                                                        pediatric
                                                        patients who were
                                                        subsequently found to have undiagnosed skeletal muscle myopathy,
                                                        most
                                                        frequently Duchenne's
                                                        muscular dystrophy. Although some patients will have no
                                                        identifiable
                                                        risk
                                                        factors, a careful history
                                                        and physical exam may identify developmental delays suggestive
                                                        of
                                                        myopathy,
                                                        and a preoperative
                                                        creatinine kinase could identify some patients at risk. When
                                                        succinylcholine
                                                        is used in pediatric
                                                        patients, closely monitor body temperature, expired CO2, heart
                                                        rate,
                                                        blood
                                                        pressure, and
                                                        electrocardiogram; careful monitoring may help detect early
                                                        signs of
                                                        malignant hyperthermia and/or
                                                        hyperkalemia. The rhabdomyolysis syndrome often presents as
                                                        peaked
                                                        T-waves
                                                        and sudden
                                                        cardiac arrest within minutes after succinylcholine
                                                        administration.
                                                        Many
                                                        affected patients are males
                                                        and 8 years of age or younger; however, cases have also been
                                                        reported in
                                                        females and
                                                        adolescents. Bradycardia, which may progress to asystole, has
                                                        also
                                                        been
                                                        reported more commonly
                                                        in infants and children, as well as in patients receiving
                                                        repeated
                                                        doses,
                                                        intravenous administration
                                                        (compared to intramuscular administration), or concurrent agents
                                                        that have
                                                        negative chronotropic
                                                        effects (e.g., halothane, propofol, fentanyl). Pretreatment with
                                                        anticholinergic agents (e.g., atropine)
                                                        may reduce the occurrence of bradyarrhythmias. If cardiac arrest
                                                        occurs
                                                        immediately after the
                                                        administration of succinylcholine, hyperkalemia should be
                                                        suspected
                                                        and
                                                        managed accordingly
                                                        (e.g., intravenous calcium, bicarbonate, glucose with insulin,
                                                        hyperventilation). In the presence of
                                                        signs of malignant hyperthermia, appropriate treatment (e.g.,
                                                        dantrolene,
                                                        supportive care) should be
                                                        initiated concurrently. Because it is difficult to identify
                                                        which
                                                        patients
                                                        are at risk, it is
                                                        recommended
                                                        that succinylcholine use in pediatric patients should be
                                                        reserved
                                                        for
                                                        emergency intubation or
                                                        instances where immediate securing of the airway is necessary
                                                        (e.g.,
                                                        laryngospasm, difficult airway,
                                                        full stomach, or lack of intravenous access); for routine
                                                        elective
                                                        surgery,
                                                        pediatric patients should
                                                        receive nondepolarizing neuromuscular agents.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseFour"
                                                role="button" aria-expanded="false"
                                                aria-controls="Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseFour">
                                                Glaucoma, ocular surgery, ocular trauma
                                            </a>
                                            <div class="card collapse"
                                                id="Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseFour"
                                                data-parent="#Succinylcholine-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Succinylcholine increases intraocular pressure and should be
                                                        used
                                                        cautiously
                                                        when increased
                                                        intraocular pressure is undesirable, (e.g., narrow angle
                                                        glaucoma,
                                                        penetrating ocular trauma, ocular
                                                        surgery).
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseFive"
                                                role="button" aria-expanded="false"
                                                aria-controls="Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseFive">
                                                Labor, obstetric delivery, pregnancy
                                            </a>
                                            <div class="card collapse"
                                                id="Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseFive"
                                                data-parent="#Succinylcholine-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Use succinylcholine during pregnancy only if clearly needed.
                                                        Reduced
                                                        plasma
                                                        cholinesterase
                                                        activity may occur in pregnancy; a higher proportion of patients
                                                        may
                                                        experience prolonged apnea to
                                                        succinylcholine when pregnant compared to nonpregnant females.
                                                        Succinylcholine is used during
                                                        labor and obstetric delivery by cesarean section. After a single
                                                        dose of 1
                                                        mg/kg to the mother, small
                                                        amounts of the drug do enter the fetal circulation but not in an
                                                        amount that
                                                        would endanger the
                                                        fetus. However, the amount of drug that enters the fetal
                                                        circulation
                                                        is
                                                        dependent on the
                                                        concentration gradient between maternal and fetal circulations.
                                                        Therefore,
                                                        residual neuromuscular
                                                        blockage (i.e., apnea and flaccidity) may occur in the neonate
                                                        after
                                                        repeated high doses or in the
                                                        presence of atypical plasma cholinesterase in the mother.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseSix"
                                                role="button" aria-expanded="false"
                                                aria-controls="Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseSix">
                                                Breast-feeding
                                            </a>
                                            <div class="card collapse"
                                                id="Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseSix"
                                                data-parent="#Succinylcholine-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        It is not known if succinylcholine is excreted in human breast
                                                        milk.
                                                        Because
                                                        many drugs are
                                                        excreted in human milk, use caution after administering
                                                        succinylcholine to a
                                                        breast-feeding woman.
                                                        However, the drug is rapidly eliminated and has poor oral
                                                        absorption, so it
                                                        is not likely to reach the
                                                        circulation or cause adverse effects in breast-fed infants.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseSeven"
                                                role="button" aria-expanded="false"
                                                aria-controls="Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseSeven">
                                                Anemia, cardiac disease, cholinesterase inhibitor
                                                toxicity, edema, hepatic
                                                disease, infection, malnutrition, myxedema, peptic ulcer disease,
                                                pseudocholinesterase deficiency, renal disease
                                            </a>
                                            <div class="card collapse"
                                                id="Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseSeven"
                                                data-parent="#Succinylcholine-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Succinylcholine is metabolized by plasma cholinesterase and
                                                        should
                                                        be used
                                                        with great caution in
                                                        patients with reduced plasma cholinesterase activity because
                                                        prolonged
                                                        neuromuscular blockade
                                                        may occur. Plasma cholinesterase activity may be diminished in
                                                        pseudocholinesterase deficiency
                                                        (e.g., patients heterozygous or homozygous for atypical plasma
                                                        cholinesterase gene), anemia,
                                                        dehydration, malnutrition, pregnancy, severe hepatic disease,
                                                        severe
                                                        renal
                                                        disease, malignant
                                                        tumors, infection, burns, decompensated cardiac disease, peptic
                                                        ulcer
                                                        disease, myxedema, or
                                                        recent plasmapheresis therapy. In addition, irreversible
                                                        inhibitors
                                                        of
                                                        plasma cholinesterase (e.g.,
                                                        organophosphate insecticides [cholinesterase inhibitor
                                                        toxicity],
                                                        cyclophosphamide) and chronic
                                                        administration of certain drugs (e.g., oral contraceptives,
                                                        glucocorticoids)
                                                        may reduce plasma
                                                        cholinesterase activity. It is important to note that onset of
                                                        neuromuscular
                                                        blockade may be delayed
                                                        in patients with cardiac disease or other conditions associated
                                                        with
                                                        poor
                                                        circulation and edema.
                                                        Subsequent doses should be administered with caution in any
                                                        patient
                                                        with a
                                                        predisposition to
                                                        delayed onset or prolonged duration of paralysis.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseEight"
                                                role="button" aria-expanded="false"
                                                aria-controls="Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseEight">
                                                Myasthenia gravis, neuromuscular disease, obesity
                                            </a>
                                            <div class="card collapse"
                                                id="Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseEight"
                                                data-parent="#Succinylcholine-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Patients with conditions that impair neuromuscular function can
                                                        experience
                                                        prolonged or
                                                        exaggerated neuromuscular blockade after receiving neuromuscular
                                                        blocking
                                                        agents. These
                                                        conditions include myasthenia gravis, myasthenic syndrome (Eaton
                                                        Lambert
                                                        syndrome), myopathy,
                                                        or any other neuromuscular disease. Because myasthenia gravis
                                                        involves
                                                        destruction of
                                                        acetylcholine receptors instead of receptor upregulation, as
                                                        seen in
                                                        other
                                                        neuromuscular diseases,
                                                        these patients tend to be less sensitive to the effects of
                                                        succinylcholine
                                                        compared to nondepolarizing
                                                        agents (e.g., rocuronium, vecuronium). In addition to
                                                        neuromuscular
                                                        disease,
                                                        patients with weak
                                                        muscle tone and those who suffer from severe obesity are at an
                                                        increased
                                                        risk for airway and
                                                        ventilation complications. Use succinylcholine with caution in
                                                        patients with
                                                        these conditions, and
                                                        continue to monitor patients carefully until recovery is fully
                                                        complete.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseNine"
                                                role="button" aria-expanded="false"
                                                aria-controls="Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseNine">
                                                Accidental exposure, requires a specialized care
                                                setting, requires an
                                                experienced
                                                clinician, respiratory insufficiency
                                            </a>
                                            <div class="card collapse"
                                                id="Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseNine"
                                                data-parent="#Succinylcholine-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Administration of succinylcholine requires an experienced
                                                        clinician
                                                        familiar
                                                        with the actions,
                                                        characteristics, and hazards of neuromuscular blockade.
                                                        Neuromuscular
                                                        blocking agents (NMBAs)
                                                        cause respiratory insufficiency by paralyzing respiratory
                                                        muscles;
                                                        administration requires a
                                                        specialized care setting. Use succinylcholine only when
                                                        necessary
                                                        equipment
                                                        and personnel skilled
                                                        in airway management are immediately available. Adequacy of
                                                        respiration must
                                                        be assured through
                                                        assisted or controlled ventilation. Accidental exposure to a
                                                        NMBA in
                                                        a
                                                        patient for whom it is not
                                                        intended can be fatal. Confirm proper medication selection and
                                                        store
                                                        NMBAs
                                                        with the cap and
                                                        ferrule intact, in a manner that minimizes the possibility of
                                                        selecting the
                                                        wrong product. Ensure that
                                                        the intended dose is clearly labeled and communicated.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseTen"
                                                role="button" aria-expanded="false"
                                                aria-controls="Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseTen">
                                                Neuromuscular blocking agent hypersensitivity
                                            </a>
                                            <div class="card collapse"
                                                id="Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseTen"
                                                data-parent="#Succinylcholine-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Succinylcholine is contraindicated in patients known to have a
                                                        succinylcholine chloride
                                                        hypersensitivity. Although rare, severe anaphylactic or
                                                        anaphylactoid
                                                        reactions to neuromuscular
                                                        blockers, including succinylcholine, have been reported; some
                                                        cases
                                                        have
                                                        been life-threatening and
                                                        fatal. Succinylcholine should be used with caution in patients
                                                        with
                                                        a
                                                        neuromuscular blocking agent
                                                        hypersensitivity, as cross-reactivity has been reported with
                                                        both
                                                        depolarizing and nondepolarizing
                                                        agents in this class. Immediate availability of appropriate
                                                        emergency
                                                        treatment for anaphylaxis is
                                                        advised.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseEleven"
                                                role="button" aria-expanded="false"
                                                aria-controls="Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseEleven">
                                                Asthma, chronic lung disease (CLD), chronic
                                                obstructive pulmonary disease
                                                (COPD), pulmonary disease, respiratory depression
                                            </a>
                                            <div class="card collapse"
                                                id="Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseEleven"
                                                data-parent="#Succinylcholine-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Use neuromuscular blocking agents (NMBAs), including
                                                        succinylcholine, with
                                                        caution in patients with
                                                        asthma or other pulmonary conditions. NMBAs stimulate histamine
                                                        release,
                                                        which could exacerbate
                                                        asthma. Histamine-mediated effects (e.g., flushing, hypotension,
                                                        bronchoconstriction) are
                                                        uncommon in normal clinical usage of succinylcholine; however
                                                        any
                                                        NMBA
                                                        should be used with
                                                        caution in those with any condition in which a release of
                                                        histamine
                                                        may be
                                                        contraindicated. In
                                                        addition, NMBAs cause respiratory muscle paralysis; residual
                                                        muscle
                                                        weakness
                                                        and decreased
                                                        respiratory function (respiratory depression) can persist even
                                                        after
                                                        drug
                                                        discontinuation. Use NMBAs
                                                        with caution in patients with pulmonary disease and conditions
                                                        associated
                                                        with low pulmonary
                                                        function reserve, such as neonatal chronic lung disease (CLD) or
                                                        chronic
                                                        obstructive pulmonary
                                                        disease (COPD). Carefully monitor respiratory status and
                                                        adequacy of
                                                        ventilation after drug recovery
                                                        until the patient is clearly stabilized.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseTwelve"
                                                role="button" aria-expanded="false"
                                                aria-controls="Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseTwelve">
                                                Acid/base imbalance, adrenal insufficiency,
                                                dehydration, electrolyte imbalance,
                                                hypercalcemia, hypermagnesemia, hypocalcemia, hypokalemia, hypothermia,
                                                metabolic acidosis, metabolic alkalosis, respiratory acidosis,
                                                respiratory
                                                alkalosis
                                            </a>
                                            <div class="card collapse"
                                                id="Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseTwelve"
                                                data-parent="#Succinylcholine-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Various physiologic states can alter the expected effects of
                                                        succinylcholine; carefully consider each
                                                        patient's clinical condition when dosing succinylcholine and
                                                        monitoring the
                                                        patient. Cachectic and
                                                        debilitated patients are more sensitive to neuromuscular
                                                        blocking
                                                        agents.
                                                        Electrolyte imbalance can
                                                        alter a patient's sensitivity to neuromuscular blocking agents
                                                        (NMBAs).
                                                        Hypercalcemia can decrease
                                                        sensitivity to NMBAs, while most other electrolyte disturbances
                                                        increase
                                                        sensitivity (e.g.,
                                                        hypokalemia, hypocalcemia, hypermagnesemia). Use succinylcholine
                                                        cautiously
                                                        in patients with
                                                        conditions that may lead to electrolyte imbalances, such as
                                                        adrenal
                                                        insufficiency. Severe acid/base
                                                        imbalance may alter a patient's sensitivity to NMBAs: metabolic
                                                        alkalosis,
                                                        metabolic acidosis, and
                                                        respiratory acidosis may enhance neuromuscular blockade and/or
                                                        prolong
                                                        recovery time, while
                                                        respiratory alkalosis reduces the potency of the drug.
                                                        Dehydration
                                                        and
                                                        hypothermia can also
                                                        increase a patient's sensitivity to NMBAs.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseThriteen"
                                                role="button" aria-expanded="false"
                                                aria-controls="Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseThriteen">
                                                Increased intracranial pressure
                                            </a>
                                            <div class="card collapse"
                                                id="Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseThriteen"
                                                data-parent="#Succinylcholine-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Succinylcholine may cause a transient increased intracranial
                                                        pressure;
                                                        adequate anesthetic
                                                        induction prior to administration will minimize this effect.
                                                        Additionally,
                                                        intragastric pressure may
                                                        increase with succinylcholine administration, possibly resulting
                                                        in
                                                        regurgitation and aspiration of
                                                        stomach contents.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseFourteen"
                                                role="button" aria-expanded="false"
                                                aria-controls="Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseFourteen">
                                                Bone fractures
                                            </a>
                                            <div class="card collapse"
                                                id="Succinylcholine-CONTRAINDICATIONS-PRECAUTIONScollapseFourteen"
                                                data-parent="#Succinylcholine-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Initial muscle fasciculations associated with succinylcholine
                                                        administration
                                                        can
                                                        cause additional injury in patients with bone fractures or
                                                        muscle
                                                        spasms.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                    </ul>
                                </div>
                            </div>
                        </div>
                        <div class="card">
                            <a class="collapsed" data-toggle="collapse" href="#SuccinylcholineCollapseThree"
                                role="button" aria-expanded="false" aria-controls="SuccinylcholineCollapseThree">
                                <div class="card-header" id="SuccinylcholineheadingThree">
                                    <h1 class="card-heading">
                                        BOXED WARNING
                                    </h1>
                                </div>
                            </a>
                            <div id="SuccinylcholineCollapseThree" class="collapse"
                                aria-labelledby="SuccinylcholineheadingThree" data-parent="#Succinylcholine">
                                <div class="card-body" id="Succinylcholine-CONTRAINDICATIONS-PRECAUTIONS">

                                    <h5>Burns, digitalis toxicity, Guillain-Barre syndrome, hyperkalemia, trauma</h5>

                                    Succinylcholine is contraindicated in patients after the acute phase of injury after
                                    major burns,
                                    multiple trauma, extensive denervation of skeletal muscle, or upper motor neuron
                                    injury.
                                    Succinylcholine administration to such patients can cause severe hyperkalemia, which
                                    can result in
                                    cardiac arrest. Risk for hyperkalemia in such patients increases over time and
                                    usually peaks 7 to 10
                                    days after the injury; however, the precise onset and duration of the risk period
                                    are unknown. Risk is
                                    dependent on extent and location of injury. Additionally, succinylcholine should be
                                    administered with
                                    great caution in patients with electrolyte imbalances and those who take digoxin and
                                    may have
                                    digitalis toxicity, as succinylcholine-induced hyperkalemia may cause serious
                                    cardiac arrhythmias
                                    and cardiac arrest. Succinylcholine should not be used in any patient with a serum
                                    potassium more
                                    than 5.5 mEq/L. Chronic abdominal infections, subarachnoid hemorrhage, tetanus,
                                    disuse atrophy,
                                    Guillain-Barre syndrome, and degenerative nervous system disorders may also increase
                                    the risk for
                                    hyperkalemia.

                                    <br><br>
                                    <h5>Bradycardia, children, infants, malignant hyperthermia, myopathy, neonates,
                                        rhabdomyolysis
                                    </h5>

                                    Succinylcholine is contraindicated in patients with a personal or familial history
                                    of malignant
                                    hyperthermia and/or skeletal muscle myopathy. Malignant hyperthermia may be
                                    precipitated by
                                    succinylcholine; concomitant use of volatile anesthetics may further increase the
                                    risk of developing
                                    this hypermetabolic state. Use succinylcholine with caution in neonates, infants,
                                    children, and
                                    adolescents; in general, the use of succinylcholine should be limited to very urgent
                                    clinical situations.
                                    There have been rare reports of ventricular dysrhythmias and fatal cardiac arrest
                                    secondary to
                                    rhabdomyolysis with hyperkalemia, primarily in healthy appearing pediatric patients
                                    who were
                                    subsequently found to have undiagnosed skeletal muscle myopathy, most frequently
                                    Duchenne's
                                    muscular dystrophy. Although some patients will have no identifiable risk factors, a
                                    careful history
                                    and physical exam may identify developmental delays suggestive of myopathy, and a
                                    preoperative
                                    creatinine kinase could identify some patients at risk. When succinylcholine is used
                                    in pediatric
                                    patients, closely monitor body temperature, expired CO2, heart rate, blood pressure,
                                    and
                                    electrocardiogram; careful monitoring may help detect early signs of malignant
                                    hyperthermia and/or
                                    hyperkalemia. The rhabdomyolysis syndrome often presents as peaked T-waves and
                                    sudden
                                    cardiac arrest within minutes after succinylcholine administration. Many affected
                                    patients are males
                                    and 8 years of age or younger; however, cases have also been reported in females and
                                    adolescents. Bradycardia, which may progress to asystole, has also been reported
                                    more commonly
                                    in infants and children, as well as in patients receiving repeated doses,
                                    intravenous administration
                                    (compared to intramuscular administration), or concurrent agents that have negative
                                    chronotropic
                                    effects (e.g., halothane, propofol, fentanyl). Pretreatment with anticholinergic
                                    agents (e.g., atropine)
                                    may reduce the occurrence of bradyarrhythmias. If cardiac arrest occurs immediately
                                    after the
                                    administration of succinylcholine, hyperkalemia should be suspected and managed
                                    accordingly
                                    (e.g., intravenous calcium, bicarbonate, glucose with insulin, hyperventilation). In
                                    the presence of
                                    signs of malignant hyperthermia, appropriate treatment (e.g., dantrolene, supportive
                                    care) should be
                                    initiated concurrently. Because it is difficult to identify which patients are at
                                    risk, it is recommended
                                    that succinylcholine use in pediatric patients should be reserved for emergency
                                    intubation or
                                    instances where immediate securing of the airway is necessary (e.g., laryngospasm,
                                    difficult airway,
                                    full stomach, or lack of intravenous access); for routine elective surgery,
                                    pediatric patients should
                                    receive nondepolarizing neuromuscular agents.
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="tab-pane" id="Vecuronium" role="tabpanel" aria-labelledby="Vecuronium-tab">
                <div class="mainContent">
                    <div id="Vecuronium">
                        <div class="card">
                            <a class="collapsed" data-toggle="collapse" href="#VecuroniumCollapseOne" role="button"
                                aria-expanded="false" aria-controls="VecuroniumCollapseOne">
                                <div class="card-header" id="VecuroniumheadingOne">
                                    <h1 class="card-heading">
                                        Dosing
                                    </h1>
                                </div>
                            </a>
                            <div id="VecuroniumCollapseOne" class="collapse" aria-labelledby="VecuroniumheadingOne"
                                data-parent="#Vecuronium">
                                <div class="card-body" id="Vecuronium-Dosing">
                                    <ul>
                                        <li>
                                            <a data-toggle="collapse" href="#Vecuronium-DosingcollapseOne" role="button"
                                                aria-expanded="false" aria-controls="Vecuronium-DosingcollapseOne">
                                                DOSAGE &amp; INDICATIONS
                                            </a>
                                            <div class="card collapse" id="Vecuronium-DosingcollapseOne"
                                                data-parent="#Vecuronium-Dosing">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        <h3>For muscular relaxation during rapid-sequence intubation
                                                            (RSI).
                                                            Intravenous dosage</h3>
                                                        <h4>Adults</h4>
                                                        0.15 mg/kg/dose IV has been recommended. Onset of intubating
                                                        conditions is 2
                                                        to 3 minutes.
                                                        <h4>Infants, Children, and Adolescents 7 weeks to 17 years</h4>
                                                        0.15 to 0.2 mg/kg/dose IV. Onset of intubating conditions is 2
                                                        to 3
                                                        minutes
                                                        and duration is typically
                                                        25 to 120 minutes depending on the age of the patient. In
                                                        general,
                                                        infants
                                                        and adolescents
                                                        experience a longer duration of action than children.
                                                        <h4>Neonates and Infants younger than 7 weeks</h4>
                                                        0.1 mg/kg/dose IV. Onset of intubating conditions is 2 to 3
                                                        minutes
                                                        and
                                                        duration is typically 30 to 40
                                                        minutes
                                                        <h4>For the maintenance of neuromuscular blockade and paralysis
                                                            .
                                                            For neuromuscular blockade in adult patients as an adjunct
                                                            to
                                                            general
                                                            anesthesia
                                                            induction in patients anesthetized with enflurane or
                                                            isoflurane.
                                                        </h4>
                                                        <h4>Intravenous dosage</h4>
                                                        <h4>Adults</h4>
                                                        Initially, 0.06 to 0.085 mg/kg IV. Then maintain blockade with
                                                        0.01
                                                        to 0.015
                                                        mg/kg IV after 25 to 40
                                                        minutes, and then every 12 to 15 minutes, or as needed.
                                                        Alternatively, 1
                                                        mcg/kg/minute (0.06
                                                        mg/kg/hour) by IV infusion can be given after the effects of the
                                                        initial
                                                        dose begin to subside, then
                                                        adjusted to attain clinical goals.
                                                        <h4>For neuromuscular blockade in adult patients as an adjunct
                                                            to
                                                            surgical
                                                            anesthesia following succinylcholine assisted endotracheal
                                                            intubation.
                                                        </h4>
                                                        <h4>Intravenous dosage</h4>
                                                        <h4>Adults</h4>
                                                        0.04 to 0.06 mg/kg IV under inhalation anesthesia, or 0.05 to
                                                        0.06
                                                        mg/kg IV
                                                        under balanced
                                                        anesthesia. The effects of succinylcholine should be allowed to
                                                        subside
                                                        before administering
                                                        vecuronium.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse" href="#Vecuronium-DosingcollapseTwo" role="button"
                                                aria-expanded="false" aria-controls="Vecuronium-DosingcollapseTwo">
                                                MAXIMUM DOSAGE
                                            </a>
                                            <div class="card collapse" id="Vecuronium-DosingcollapseTwo"
                                                data-parent="#Vecuronium-Dosing">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Specific maximum dosage information is not available. Dosage
                                                        must be
                                                        individualized
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse" href="#Vecuronium-DosingcollapseThree"
                                                role="button" aria-expanded="false"
                                                aria-controls="Vecuronium-DosingcollapseThree">
                                                DOSING CONSIDERATIONS
                                            </a>
                                            <div class="card collapse" id="Vecuronium-DosingcollapseThree"
                                                data-parent="#Vecuronium-Dosing">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        <h4>Hepatic Impairment</h4>
                                                        Hepatic impairment may prolong the duration of action of
                                                        vecuronium.
                                                        Specific guidelines for dosage
                                                        adjustments in hepatic impairment are not available; dosage
                                                        reduction or
                                                        extended dosing interval
                                                        may be necessary.
                                                        <h4>Renal Impairment</h4>
                                                        Renal failure may prolong the duration of action of vecuronium.
                                                        Specific
                                                        guidelines for dosage
                                                        adjustments in patients with renal impairment and failure are
                                                        not
                                                        available;
                                                        dosage reduction or
                                                        extended dosing interval may be necessary in patients with renal
                                                        failure.
                                                        However, the manufacturer
                                                        states that if prepared well for surgery with dialysis, patients
                                                        with renal
                                                        failure tolerate vecuronium
                                                        well without a significant prolongation of clinical effect. If
                                                        anephric
                                                        patients cannot be prepared for
                                                        surgery with dialysis, a lower initial dose should be
                                                        considered.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                    </ul>
                                </div>
                            </div>
                        </div>
                        <div class="card">
                            <a class="collapsed" data-toggle="collapse" href="#VecuroniumCollapseTwo" role="button"
                                aria-expanded="false" aria-controls="VecuroniumCollapseTwo">
                                <div class="card-header" id="VecuroniumheadingTwo">
                                    <h1 class="card-heading">
                                        CONTRAINDICATIONS / PRECAUTIONS
                                    </h1>
                                </div>
                            </a>
                            <div id="VecuroniumCollapseTwo" class="collapse" aria-labelledby="VecuroniumheadingTwo"
                                data-parent="#Vecuronium">
                                <div class="card-body" id="Vecuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                    <ul>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseOne"
                                                role="button" aria-expanded="false"
                                                aria-controls="Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseOne">
                                                General Information
                                            </a>
                                            <div class="card collapse"
                                                id="Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseOne"
                                                data-parent="#Vecuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Vecuronium does not cause sedation or analgesia and should be
                                                        administered
                                                        only after
                                                        unconsciousness has been induced. Amnesia and analgesia should
                                                        be
                                                        adequately
                                                        maintained
                                                        throughout paralyzation. Doses of vecuronium should be
                                                        individualized. Use
                                                        of a peripheral nerve
                                                        stimulator will permit the most advantageous use of vecuronium,
                                                        minimize the
                                                        possibility of
                                                        overdosage or underdosage, and assist in the evaluation of
                                                        recovery.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseTwo"
                                                role="button" aria-expanded="false"
                                                aria-controls="Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseTwo">
                                                Accidental exposure, requires a specialized care
                                                setting, requires an
                                                experienced
                                                clinician, respiratory insufficiency
                                            </a>
                                            <div class="card collapse"
                                                id="Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseTwo"
                                                data-parent="#Vecuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Administration of vecuronium requires an experienced clinician
                                                        familiar with
                                                        the actions,
                                                        characteristics, and hazards of neuromuscular blockade.
                                                        Neuromuscular
                                                        blocking agents (NMBAs)
                                                        cause respiratory insufficiency by paralyzing respiratory
                                                        muscles;
                                                        administration requires a
                                                        specialized care setting. Use vecuronium only when necessary
                                                        equipment and
                                                        personnel skilled in
                                                        airway management are immediately available. Adequacy of
                                                        respiration
                                                        must be
                                                        assured through
                                                        assisted or controlled ventilation. Reversal agents should also
                                                        be
                                                        available. Accidental exposure to a
                                                        NMBA in a patient for whom it is not intended can be fatal.
                                                        Confirm
                                                        proper
                                                        medication selection and
                                                        store NMBAs with the cap and ferrule intact, in a manner that
                                                        minimizes the
                                                        possibility of selecting
                                                        the wrong product. Ensure that the intended dose is clearly
                                                        labeled
                                                        and
                                                        communicated.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseThree"
                                                role="button" aria-expanded="false"
                                                aria-controls="Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseThree">
                                                Bromide hypersensitivity, neuromuscular blocking
                                                agent hypersensitivity
                                            </a>
                                            <div class="card collapse"
                                                id="Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseThree"
                                                data-parent="#Vecuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Vecuronium is contraindicated in patients known to have a
                                                        vecuronium
                                                        bromide
                                                        hypersensitivity.
                                                        Although rare, severe anaphylactic or anaphylactoid reactions to
                                                        neuromuscular blockers have been
                                                        reported; some cases have been fatal. Vecuronium should be used
                                                        with
                                                        caution
                                                        in patients with a
                                                        neuromuscular blocking agent hypersensitivity, as
                                                        cross-reactivity
                                                        has been
                                                        reported with both
                                                        depolarizing and non-depolarizing agents in this class.
                                                        Immediate
                                                        availability of appropriate
                                                        emergency treatment for anaphylaxis is advised.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseFour"
                                                role="button" aria-expanded="false"
                                                aria-controls="Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseFour">
                                                Acid/base imbalance, adrenal insufficiency,
                                                dehydration, electrolyte imbalance,
                                                hypercalcemia, hypermagnesemia, hypocalcemia, hypokalemia, hypothermia,
                                                metabolic acidosis, metabolic alkalosis, respiratory acidosis,
                                                respiratory
                                                alkalosis
                                            </a>
                                            <div class="card collapse"
                                                id="Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseFour"
                                                data-parent="#Vecuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Various physiologic states can alter the expected effects of
                                                        vecuronium;
                                                        carefully consider each
                                                        patient's clinical condition when dosing vecuronium and
                                                        monitoring
                                                        the
                                                        patient. Cachectic and
                                                        debilitated patients are more sensitive to neuromuscular
                                                        blocking
                                                        agents.
                                                        Electrolyte imbalance can
                                                        alter a patient's sensitivity to NMBAs. Hypercalcemia can
                                                        decrease
                                                        sensitivity to NMBAs, while most
                                                        other electrolyte disturbances increase sensitivity (e.g.,
                                                        hypokalemia,
                                                        hypocalcemia,
                                                        hypermagnesemia). Use rocuronium cautiously in patients with
                                                        conditions that
                                                        may lead to
                                                        electrolyte imbalances, such as adrenal insufficiency. Severe
                                                        acid/base
                                                        imbalance may alter a
                                                        patient's sensitivity to NMBAs: metabolic alkalosis, metabolic
                                                        acidosis, and
                                                        respiratory acidosis may
                                                        enhance neuromuscular blockade and/or prolong recovery time,
                                                        while
                                                        respiratory alkalosis reduces
                                                        the potency of the drug. Dehydration and hypothermia can also
                                                        increase a
                                                        patient's sensitivity to
                                                        NMBAs.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseFive"
                                                role="button" aria-expanded="false"
                                                aria-controls="Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseFive">
                                                Asthma, chronic lung disease (CLD), chronic obstructive pulmonary
                                                disease
                                                (COPD), pulmonary disease, respiratory depression
                                            </a>
                                            <div class="card collapse"
                                                id="Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseFive"
                                                data-parent="#Vecuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Use neuromuscular blocking agents (NMBAs), including vecuronium,
                                                        with
                                                        caution in patients with
                                                        asthma or other pulmonary conditions. NMBAs stimulate histamine
                                                        release,
                                                        which could exacerbate
                                                        asthma. Compared with other NMBAs, vecuronium produces little or
                                                        no
                                                        histamine release. While
                                                        some experts consider vecuronium to be an NMBA of choice in
                                                        asthmatic
                                                        patients, it should be used
                                                        with caution in those with any condition in which a significant
                                                        release of
                                                        histamine may be
                                                        contraindicated. In addition, NMBAs cause respiratory muscle
                                                        paralysis;
                                                        residual muscle weakness
                                                        and decreased respiratory function (respiratory depression) can
                                                        persist even
                                                        after drug
                                                        discontinuation. Use NMBAs with caution in patients with
                                                        pulmonary
                                                        disease
                                                        and conditions
                                                        associated with low pulmonary function reserve, such as chronic
                                                        obstructive
                                                        pulmonary disease
                                                        (COPD) or neonatal chronic lung disease (CLD). Carefully monitor
                                                        respiratory
                                                        status and adequacy
                                                        of ventilation after drug recovery until the patient is clearly
                                                        stabilized.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseSix"
                                                role="button" aria-expanded="false"
                                                aria-controls="Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseSix">
                                                Geriatric, myasthenia gravis, myopathy,
                                                neuromuscular disease, obesity
                                            </a>
                                            <div class="card collapse"
                                                id="Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseSix"
                                                data-parent="#Vecuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Patients with conditions that impair neuromuscular function can
                                                        experience
                                                        prolonged or
                                                        exaggerated neuromuscular blockade after receiving
                                                        nondepolarizing
                                                        agents.
                                                        These conditions
                                                        include myasthenia gravis, myasthenic syndrome (Eaton Lambert
                                                        syndrome),
                                                        myopathy, or any
                                                        other neuromuscular disease. Geriatric patients may be at
                                                        increased
                                                        risk for
                                                        residual neuromuscular
                                                        block. Additionally, patients with weak muscle tone and those
                                                        who
                                                        suffer
                                                        from severe obesity are at
                                                        an increased risk for airway and ventilation complications. Use
                                                        vecuronium
                                                        with caution in patients
                                                        with these conditions, and continue to monitor patients
                                                        carefully
                                                        until
                                                        recovery is fully complete.
                                                        Consider the use of a small test dose and a peripheral nerve
                                                        stimulator to
                                                        monitor response in these
                                                        patients.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseSeven"
                                                role="button" aria-expanded="false"
                                                aria-controls="Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseSeven">
                                                Cardiac disease, edema
                                            </a>
                                            <div class="card collapse"
                                                id="Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseSeven"
                                                data-parent="#Vecuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Use vecuronium with caution in patients with cardiac disease or
                                                        other
                                                        conditions that may be
                                                        associated with a slower circulation time. Changes in the volume
                                                        of
                                                        distribution related to poor
                                                        circulation or edema can delay the onset of neuromuscular
                                                        blockade.
                                                        Particular care is required in
                                                        administering subsequent doses when it is uncertain whether
                                                        maximum
                                                        effect
                                                        has been attained.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseEight"
                                                role="button" aria-expanded="false"
                                                aria-controls="Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseEight">
                                                Hepatic disease
                                            </a>
                                            <div class="card collapse"
                                                id="Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseEight"
                                                data-parent="#Vecuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Since significant amounts of vecuronium are excreted via the
                                                        bile,
                                                        patients
                                                        with hepatic disease
                                                        should be treated with caution. There can be a prolonged
                                                        recovery
                                                        from
                                                        neuromuscular blockade.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseNine"
                                                role="button" aria-expanded="false"
                                                aria-controls="Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseNine">
                                                Renal failure, uremia
                                            </a>
                                            <div class="card collapse"
                                                id="Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseNine"
                                                data-parent="#Vecuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Use vecuronium with caution in patients with renal failure.
                                                        Though
                                                        vecuronium is primarily
                                                        dependent on hepatic clearance, hepatic elimination is decreased
                                                        in
                                                        patients
                                                        with uremia, which may
                                                        lead to an accumulation of the 3-desacetyl active metabolite.
                                                        Prolonged
                                                        recovery due to active
                                                        metabolite and parent drug accumulation may be seen in this
                                                        population.
                                                        According to the
                                                        manufacturer, vecuronium is well tolerated in patients with
                                                        renal
                                                        failure
                                                        who have been optimally
                                                        prepared for surgery by dialysis. However, in situations where
                                                        pre-operative
                                                        dialysis is not possible,
                                                        a lower initial dose should be considered.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseTen"
                                                role="button" aria-expanded="false"
                                                aria-controls="Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseTen">
                                                Malignant hyperthermia
                                            </a>
                                            <div class="card collapse"
                                                id="Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseTen"
                                                data-parent="#Vecuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Patients with a familial history of malignant hyperthermia
                                                        should be
                                                        treated
                                                        with extreme caution.
                                                        The condition can be precipitated by the use of halogenated
                                                        anesthetics
                                                        since this reaction has been
                                                        attributed to their use, but neuromuscular blocking agents (such
                                                        as
                                                        vecuronium) also may be a
                                                        contributory factor.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseEleven"
                                                role="button" aria-expanded="false"
                                                aria-controls="Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseEleven">
                                                Burns
                                            </a>
                                            <div class="card collapse"
                                                id="Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseEleven"
                                                data-parent="#Vecuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Patients with burns have a decreased sensitivity to vecuronium's
                                                        ability to
                                                        produce neuromuscular
                                                        blockade. Resistance to blockade usually develops in patients
                                                        with
                                                        burns
                                                        more than 10% total body
                                                        surface area approximately 1 week after thermal injury.
                                                        Increased
                                                        doses may
                                                        be required in burn
                                                        patients; alteration in drug effect may be seen for up to 1
                                                        year. In
                                                        patients with more than 40% body
                                                        surface area involvement, significant increases in dosage
                                                        requirements
                                                        (i.e., 2.5 to 5 times the usual
                                                        dose) have been reported.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseTwelve"
                                                role="button" aria-expanded="false"
                                                aria-controls="Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseTwelve">
                                                Labor, obstetric delivery, pregnancy
                                            </a>
                                            <div class="card collapse"
                                                id="Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseTwelve"
                                                data-parent="#Vecuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Use vecuronium during pregnancy only if clearly needed. It is
                                                        not
                                                        known if
                                                        vecuronium can cause
                                                        fetal harm or affect reproduction capacity when administered to
                                                        a
                                                        pregnant
                                                        woman. Animal
                                                        reproduction studies have not been conducted with vecuronium.
                                                        Vecuronium has
                                                        been used in
                                                        patients undergoing labor and obstetric delivery via cesarean
                                                        section. After
                                                        tracheal intubation with
                                                        succinylcholine, vecuronium dosages of 0.04 mg/kg (n = 11) and
                                                        0.06
                                                        to 0.08
                                                        mg/kg (n = 20) were
                                                        administered. The umbilical venous plasma concentrations were
                                                        11% of
                                                        maternal concentrations at
                                                        delivery and mean neonate APGAR scores at 5 minutes were 9 or
                                                        more
                                                        in both
                                                        reports. The action
                                                        of neuromuscular blocking agents may be enhanced by magnesium
                                                        salts
                                                        administered for the
                                                        management of toxemia in pregnancy.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseThriteen"
                                                role="button" aria-expanded="false"
                                                aria-controls="Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseThriteen">
                                                Breast-feeding
                                            </a>
                                            <div class="card collapse"
                                                id="Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseThriteen"
                                                data-parent="#Vecuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Use vecuronium with caution in women who are breast-feeding. It
                                                        is
                                                        not known
                                                        if vecuronium is
                                                        excreted in human breast milk. The elimination half-life for
                                                        vecuronium is 1
                                                        to 2 hours. It is a
                                                        monoquaternary compound and should pass slowly through
                                                        biological
                                                        membranes.
                                                        If trace amounts
                                                        were excreted into breast milk, quaternary muscle relaxants are
                                                        poorly
                                                        absorbed from the
                                                        gastrointestinal tract. Based on these data, lactation could be
                                                        allowed as
                                                        soon as practically feasible
                                                        after surgery.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                        <li>
                                            <a data-toggle="collapse"
                                                href="#Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseFourteen"
                                                role="button" aria-expanded="false"
                                                aria-controls="Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseFourteen">
                                                Infants, neonates
                                            </a>
                                            <div class="card collapse"
                                                id="Vecuronium-CONTRAINDICATIONS-PRECAUTIONScollapseFourteen"
                                                data-parent="#Vecuronium-CONTRAINDICATIONS-PRECAUTIONS">
                                                <div class="card-content">
                                                    <div class="card-body">
                                                        Neonates and infants are more sensitive to the effects of
                                                        vecuronium
                                                        compared to older patients;
                                                        they may take up to one and a half times as long to recover from
                                                        neuromuscular blockade. Monitor
                                                        patients carefully during and after administration.
                                                    </div>
                                                </div>
                                            </div>
                                        </li>
                                    </ul>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </div>





</div>